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ABSTRACT 
Alisa Anping Suen: Role of the SIX1 Oncoprotein in Endometrial Cancer Caused by 
Neonatal Xenoestrogen Exposure 
(Under the direction of Carmen Williams) 
 
Exposure to xenoestrogens during key windows of development can lead to adverse 
female reproductive health outcomes, including cancer. In a classical model of latent hormonal 
carcinogenesis, mice exposed neonatally to the synthetic estrogen diethylstilbestrol (DES) or 
the soy phytoestrogen genistein (GEN) develop endometrial carcinomas in late adulthood. 
However, the biological mechanisms driving carcinogenesis remain unclear. In this work, I 
investigated the role of the oncofetal protein sine oculis-related homeobox 1 homolog (SIX1) in 
endometrial carcinogenesis following neonatal xenoestrogen exposure and explored the utility 
of SIX1 as a biomarker in human endometrial cancer. I showed that neonatal exposure to GEN 
or DES causes aberrant endometrial SIX1 expression that persists with age and localizes to 
abnormally differentiated cell populations and all endometrial carcinomas. Further morphologic 
and molecular characterization revealed that mice exposed neonatally to GEN or DES exhibited 
three populations of abnormally differentiated SIX1-labeled endometrial epithelial cells that were 
associated with precursor lesions and carcinomas. These findings suggest that neonatal 
xenoestrogen exposure establishes unique SIX1-labeled cell populations that are associated 
with abnormal differentiation patterns in the endometrium and that may act as cancer progenitor 
cell populations. To explore the functional role of SIX1 in endometrial carcinogenesis, I used 
genetically engineered mouse models to investigate if SIX1 is necessary or sufficient for cancer 
development. I found that SIX1 was not necessary for development of xenoestrogen-induced 
endometrial carcinoma, but instead mediated abnormal differentiation of xenoestrogen-induced 
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cell types. In addition, I showed that SIX1 overexpression alone is not sufficient to induce 
endometrial carcinoma development. I investigated the relevance of SIX1 as a human 
endometrial cancer biomarker and showed that a subset of human endometrial carcinoma 
biopsies express SIX1 and that expression is associated with late-stage disease. Together, I 
provide compelling evidence that although SIX1 alone does not act as a molecular driver of 
xenoestrogen-induced endometrial carcinogenesis, it is a biomarker for xenoestrogen exposure 
and for disease development, it is expressed in a potential cancer progenitor cell population in 
mice, and it contributes to abnormal endometrial epithelial differentiation. 
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If I have seen further, it is by standing on the shoulders of giants. 
- Sir Isaac Newton 
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CHAPTER 1 – INTRODUCTION 
 
There is now widespread acceptance of the idea that environmental and stochastic 
factors that modify gene expression early in life may determine disease susceptibility later in life 
through epigenomic alterations. However, the molecular mechanisms that define the 
relationships between early environmental cues and disease phenotypes are poorly understood, 
in large part because these interactions are complex, difficult to quantify accurately, and may 
occur over long periods of time. In human studies and animal models, environmental exposures 
during critical stages of female reproductive tract development can establish permanent 
epigenomic alterations that contribute to adverse adult phenotypes, including infertility and 
cancer (Masse et al., 2009; Kurita, 2011; Walker and Ho, 2012; Schug et al., 2011). Exogenous 
chemicals with estrogenic activity, also known as xenoestrogens, are of particular interest due 
to their widespread presence in the environment and their association with adverse human 
health outcomes (Schug et al., 2011).  
 
The DES Story 
A notorious example of human developmental xenoestrogen exposure occurred when 
the potent synthetic estrogen diethylstilbestrol (DES) was administered to an estimated 2-10 
million pregnant women in the United States from 1938-1972 in a misguided effort to prevent 
miscarriages and premature delivery (Giusti et al., 1995; IARC, 2012; Reed and Fenton, 2013). 
Synthesized by Sir Edward Charles Dodd in 1938, DES was the first stable nonsteroidal 
estrogen that could be orally administered (Dodds et al., 1938). At the time, synthetic hormones 
were being explored for human therapy to treat disorders related to an abnormal hormonal 
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environment such as recurrent pregnancy loss (RPL) (Herbst and Anderson, 2015). 
Administration of an estrogenic chemical like DES was postulated to stimulate progesterone 
production to enable women with RPL to carry their pregnancies to term (Smith et al., 1946).  
Indeed, studies in a small cohort of women with high-risk pregnancies suggested that 
DES treatment increased progesterone levels and helped them carry their pregnancies to term 
with no teratogenic effects (Smith et al., 1946; Smith, 1948; Smith and Smith, 1949). However, 
the efficacy of this treatment was controversial from the outset. The validity of the initial findings 
in the high-risk cohort were called into question because the cohort was small, not adequately 
controlled, and participants were inherently provided improved healthcare as part of enrollment 
(Dieckmann et al., 1953). A large, randomized, double-blind, placebo-controlled follow up study 
using a similar DES dose and treatment schedule was unable to corroborate any of the findings 
in the high-risk cohort (Dieckmann et al., 1953). Nonetheless, DES became widely used as 
prophylactic treatment during pregnancy and resulted in prenatal exposure of developing 
fetuses (Giusti et al., 1995).  
In the United States, pregnant women were prescribed total doses of DES that ranged 
from 100 mg to 46,600 mg with a median dose between 3,650 and 4,000 mg (IARC, 2012; 
Reed and Fenton, 2013). DES was prescribed most often in the first trimester, to prevent 
miscarriage, and the third trimester, to prevent preterm delivery, but many studies report 
exposures for the entire duration of pregnancy (IARC, 2012; Reed and Fenton, 2013). 
Additionally, doses were often increased as pregnancy progressed. DES is readily bioavailable, 
with a primary and terminal half-life ranging from hours to days depending on enterohepatic 
recycling (Giusti et al., 1995; Reed and Fenton, 2013). Extensive variability in dose, duration of 
exposure, and route of administration has made it difficult to retrospectively determine a no-
observed-adverse-effect level (NOAEL) in developing fetuses.  
DES remained in use for over 30 years in large part because adverse effects resulting 
from exposure were not recognized until prenatally exposed women reached reproductive age. 
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In 1970, Arthur Herbst reported 7 cases of vaginal clear cell adenocarcinoma (CCA) in young 
women (15-22 years of age) in the same geographical location (Herbst and Scully, 1970). 
Previous cases of vaginal CCA were rare and only reported in older women, making this 
disease cluster highly unusual; Follow up with a case-control study revealed a strong 
association with prenatal DES exposure (Herbst et al., 1971; Giusti et al., 1995; Herbst and 
Anderson, 2015). The vaginal CCA standard incidence ratio is 39 in prenatally DES-exposed 
women and <1 in unexposed women (Troisi et al., 2007). Vaginal CCA is estimated to occur in 
1/1000 women exposed prenatally to DES (Herbst and Anderson, 2015). Of the 700 vaginal 
CCA cases that have been recorded since 1948, approximately two-thirds had a history of 
prenatal DES exposure (Palmer et al., 2000; Herbst and Anderson, 2015). Prenatal DES 
exposure has since been found to increase lifetime risk for a broad spectrum of adverse health 
outcomes including, reproductive malformations, infertility, preterm birth, and breast cancer 
(Herbst, 1981; Kaufman et al., 1986; Titus-Ernstoff et al., 2001; Palmer et al., 2006). The U.S. 
Food and Drug Administration (FDA) proscribed DES use during pregnancy in 1971 and it is no 
longer commercially available in the United States (FDA, 1972; IARC, 2012). DES is now 
categorized by the International Agency for Research on Cancer (IARC) as a known human 
carcinogen with sufficient evidence to support a causal association between prenatal DES 
exposure and vaginal CCA (IARC, 1987; IARC, 2012).   
Although DES is no longer used clinically during pregnancy, this exposure tragedy is a 
cornerstone of developmental reproductive toxicology research and provides a model example 
for the potential adverse effects of exposure to estrogenic chemicals during sensitive windows 
of development. These findings support the public health need to understand the mechanisms 
underlying latent biological effects caused by other xenoestrogens present in the environment. 
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Human Developmental Exposure to the Soy Phytoestrogen Genistein 
Currently, approximately 13% of infants in the United States consume soy-based infant 
formulas, which are a source of xenoestrogen exposure during developmentally sensitive life 
stages (McCarver et al., 2011). Soy infant formulas and other soy products contain isoflavones, 
a class of nonsteroidal molecules that are functionally similar to endogenous mammalian 
estrogens (Patisaul and Jefferson, 2010). Phytoestrogens are found naturally in legumes, 
especially soy beans, where they regulate plant-microbial interactions by providing antifungal 
properties and inducing nitrogen-fixing root nodulation (Rivera-Vargas et al., 1993; van Rhijn 
and Vanderleyden, 1995; Subramanian et al., 2006). Isoflavones exist as sugar bound 
complexes in plants and a majority of soy products but are hydrolyzed during food fermentation 
processes and in the gastrointestinal system resulting in the unconjugated and biologically 
active aglycone form (eg. genistein, daidzein) (McCarver et al., 2011; UK Committee on 
Toxicity, 2003). Although isoflavones exist as mixtures in soy products, the most abundant 
isoflavones found in soy formulas are genistin/genistein (~58-67%), followed by daidzin/daidzein 
(29-34%) (Setchell et al., 1998; Franke et al., 1998; McCarver et al., 2011).  
Infants can be exposed to genistein (GEN) directly though consumption of soy-formula 
or indirectly through consumption of breast milk from mothers who consume soy products. In 
the United States, infants on soy formula diets are exposed to 1.3-6.2 mg/kg body weight 
(BW)/day of GEN (McCarver et al., 2011). In contrast, GEN exposure in adults in the United 
States ranges from 0.005-0.05 mg/kg BW/day through consumption of a variety of soy-based 
food, beverage, and supplement products, and processed foods fortified with soy protein isolate 
(UK Committee on Toxicity, 2003; Patisaul and Jefferson, 2010; McCarver et al., 2011). Even 
GEN exposure in soy-rich vegetarian and Asian diets is generally <0.5 mg/kg BW/day 
(McCarver et al., 2011). However, these levels can cause secondary exposure to infants during 
breast feeding; plasma GEN levels in breast-fed infants whose mothers consumed soy ranges 
from 2-4.7 ng/mL (Franke et al., 2006; Cao et al., 2009). Nonetheless, plasma GEN levels are 
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~150 times higher in infants fed soy formula with recent studies showing levels close to 1000 
ng/mL (Setchell et al., 1997; Cao et al., 2009). According to the American Academy of 
Pediatrics (AAP), the only indication for soy formula in place of breast milk or cow milk-based 
formula is to maintain nutrition in infants with galactosemia or primary lactase deficiency (AAP, 
1998; Bhatia and Greer, 2008). However, infants often consume a mixture of breast milk and 
infant formula, especially during weaning and transition to solid foods (Forsyth et al., 1985; 
Setchell et al., 1997; Cao et al., 2009; McCarver et al., 2011). Despite the variety in source, 
content, and composition, the aforementioned studies indicate that soy continues to be a 
potential source of xenoestrogen exposure during developmentally sensitive windows and that 
investigating the potential adverse reproductive effects of GEN and other isoflavones remains 
environmentally relevant. 
Studies of infant GEN exposure are limited to biomonitoring, as such, controlled 
pharmacokinetic data comes only from studies of adults. Following oral exposure, GEN and 
other isoflavone-glycoside conjugates must be deglycosylated in the gut before they can be 
absorbed. In addition to primary absorption, GEN can also undergo enterohepatic recycling 
(Nielsen and Williamson, 2007). Circulating GEN exists mostly as glucuronide or sulfate 
conjugates with the bioactive aglycone form comprising only 1-3% of total plasma GEN (Nielsen 
and Williamson, 2007; Patisaul and Jefferson, 2010). The average time from oral exposure to 
maximal plasma GEN concentration is 5.7 hrs and the average elimination half-life is 9.5 hrs 
(Setchell et al., 2003; Nielsen and Williamson, 2007).  
Both positive and negative human health effects have been associated with GEN 
exposure. GEN has antioxidant and anti-inflammatory properties and can inhibit cell growth and 
proliferation pathways potentially contributing to decreased cancer incidence (Patisaul and 
Jefferson, 2010). However, most benefits of GEN exposure are attributed to its estrogenic 
properties including alleviating perimenopausal symptoms, slowed osteoporosis, and reduced 
cardiovascular disease (Patisaul and Jefferson, 2010). Of note, the purported beneficial effects 
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of GEN exposure are typically associated with adult dietary consumption rather than infants fed 
soy formula. Nonetheless, human studies associating estrogen-mediated phenotypic changes 
with adult dietary GEN exposure strongly support evidence that infant exposure can also induce 
biological estrogenic effects. Indeed, a cross-sectional cohort study found that girls fed soy 
formulas had estrogenized urogenital epithelium at six months of age that was not present in 
infants fed breast milk or cow milk-based formulas (Bernbaum et al., 2008; Harlid et al., 2016). 
Unfortunately, estrogenic effects during infancy are often associated with negative reproductive 
health outcomes. Several epidemiological studies have associated infant soy formula exposure 
with decreased time to menarche, greater duration and discomfort of menstruation, increased 
onset and prevalence of uterine fibroids, and endometriosis (Ho et al., 2016). However, the 
National Toxicology Program currently only considers adverse reproductive effects of soy infant 
formula to be of minimal concern to human health (level two on five-scale level of concern) 
(McCarver et al., 2011). Despite continued interest in both GEN and DES, the current body of 
scientific evidence indicates a lack of understanding of the basic biological processes driving 
later-life effects of developmental xenoestrogen exposure. 
 
Animal Models of Developmental Xenoestrogen Exposure 
It is inherently difficult to reliably study developmental xenoestrogen exposure in humans 
because of the plethora of chemicals humans are exposed to over their lifetime and the 
considerable length of time between developmental milestones such as birth, puberty, and 
pregnancy. Studies of endocrine disrupting chemicals in animal models have indicated that 
dose and timing of exposure are critical determinants of adverse effects. For example, low 
doses may produce different adverse effects than high doses and exposure during early life 
may cause infertility or cancer whereas exposure during a less sensitive period may not be 
harmful or could even provide beneficial effects. As such, Drs. John McLachlan and Retha 
Newbold established a developmental exposure mouse model, henceforth referred to as the 
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model of hormonal carcinogenesis, to understand the potential adverse reproductive health 
effects of early life estrogenic chemical exposures. In this model, mice are exposed to 
xenoestrogens by subcutaneous (SC) injection beginning on the day of birth (postnatal day 1 
[PND1]) through PND5 (Newbold and McLachlan, 1982). This model revealed that early life 
exposure to a variety of xenoestrogens can cause long-term female reproductive effects such 
as altered fertility, disrupted hormone signaling, abnormal morphologic development, 
nonneoplastic pathologies, and endometrial cancer (Newbold and McLachlan, 1982; Newbold et 
al., 1990; Newbold et al., 2001; Jefferson et al., 2009).  
Previous studies report >90% incidence of endometrial cancer by 18 months of age in 
both CD-1 and FVB/N strain mice that were exposed to 1 mg/kg/day of DES on PND1-5 
(Newbold et al., 1990; Couse et al., 1997). This is the most well characterized dose for the 
model of hormonal carcinogenesis. Several studies have also shown that the incidence of 
endometrial carcinogenesis in this model positively correlates with estrogenic potency as 
determined by percent increase of uterine wet weight (Newbold et al., 1990). Furthermore, 
exposure to equivalent estrogenic doses produce similar cancer incidences. For example, mice 
exposed to 0.001 mg/kg DES and 50 mg/kg GEN on PND1-5 have a comparable uterine wet 
weight gain and have a 31% and 35% endometrial cancer incidence by 18 months of age 
(Newbold et al., 2001). It is unknown whether different xenoestrogens, particularly GEN and 
DES, work through parallel mechanisms. However, the close similarities between GEN and 
DES-induced phenotypes in animal models of hormonal carcinogenesis clearly indicate that 
other environmental estrogens may have important biological effects, including increased 
cancer risk.  
Xenoestrogen induced carcinogenesis in this model is primarily attributed to estrogen 
receptor (ERα)-mediated mechanisms (Couse et al., 2001; Couse and Korach, 2004; Davis et 
al., 2012). Studies using the ERα knockout mouse model have demonstrated that ERα is 
dispensable for early female reproductive tract development (Couse and Korach, 1999). 
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However, ERα is present in the female reproductive tract at birth and can be stimulated with 
exogenous estrogens (Couse and Korach, 1999). Mutagenesis assays using 17β-estradiol (E2), 
DES, and DES analogs indicate that these estrogenic chemicals are nonmutagenic and 
therefore unlikely to mediate carcinogenesis via direct mutagenesis (Tsutsui and Barrett, 1997). 
However, both estrogens and xenoetrogens have mitogenic properties so it is possible that 
increased cell proliferation might indirectly contribute to increased mutagenesis. In addition, 
studies using Syrian hamster embryo cells show that under certain conditions E2 and DES can 
cause genetic alterations including aneuploidy and DNA-adducts in the absence of ER (Tsutsui 
and Barrett, 1997). Instead, the current body of scientific evidences indicates that the ERα-
xenoestrogen complex induces a cascade of downstream signaling pathways that directly and 
indirectly alters gene expression at both the transcript and protein level through genetic and 
epigenetic mechanisms (Couse and Korach, 1999; Newbold et al., 2007; Jefferson et al., 2011; 
Jefferson et al., 2013). However, the timing of xenoestrogen exposure during critical periods in 
female reproductive tract development is essential for developing adverse reproductive effects 
in this model, especially endometrial cancer. 
In both mice and humans, development and differentiation of the female reproductive 
tract begins during gestation and continues after birth. Female reproductive tract 
morphogenesis occurs predominantly during fetal life with Müllerian duct formation to the 
appearance of external genitalia occurring from embryonic day (E) 11.5-16.5 in mice and 
gestation week (GW) 7-16 in humans (Ho et al., 2016). In humans, female reproductive tract 
tissue differentiation begins in the second trimester and continues up to 6 years of age (Ho et 
al., 2016). In mice, this developmental window is shifted so that at birth mice have rudimentary 
reproductive tracts that undergo the majority of tissue differentiation postnatally. During the 
perinatal period, the Müllerian duct epithelium (MDE), which began as a mesoepithelium, 
expressing both epithelial and mesenchymal cell markers, receives cues from region specific 
stroma that stimulate the MDE to form the distinct stratified squamous epithelium of the vagina 
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and ectocervix, as well as the simple columnar epithelium of the endocervix, uterus, and 
oviducts (Orvis and Behringer, 2007). During neonatal life, the female reproductive tract 
continues to differentiate and the endometrium undergoes adenogenesis (Newbold and 
McLachlan, 1982; Cooke et al., 2013). As a result, this developmental window remains 
particularly sensitive to disruption by xenoestrogens. 
In addition to neonatal xenoestrogen exposure, endometrial carcinoma development in 
this mouse model also depends on further hormone exposure beginning at puberty (Newbold et 
al., 1990). Ovariectomy prior to puberty prevents endometrial carcinoma in mice that were 
neonatally exposed to DES, likely due to the absence of endogenous estrogens (Ostrander et 
al., 1985; Newbold et al., 1990). In addition, postpubertal exogenous estrogen treatment 
promotes the uterine cancer phenotype in ovariectomized Syrian hamsters that were neonatally 
exposed to DES (Leavitt et al., 1981). Mice and hamsters exposed neonatally to xenoestrogens 
are anovulatory and have continuous low-level secretion of estradiol rather than cyclical peaks 
(Leavitt et al., 1981; Jefferson et al., 2005). Together, these findings indicate that 
carcinogenesis in this model of developmental xenoestrogen exposure follows the two-hit model 
of cancer formation, where the first hit occurs during early developmental estrogen exposure 
and the second hit occurs through promotion by pubertal acquisition of endogenous hormones. 
The established mouse model of neonatal xenoestrogen exposure is based on 
subcutaneous injection of DES or GEN, where DES serves as a potent reference xenoestrogen 
and GEN serves as an environmentally relevant xenoestrogen. Thus, it is important to consider 
the relevance of GEN in this mouse model for predicting the effects of oral GEN exposure in 
infants. Pharmacokinetic studies show that when genistin was given orally at GEN-equivalent 
doses (correction for the additional molecular weight of the sugar moiety) neonatal mice had 
similar serum levels of GEN as those given a 50 mg/kg GEN dose by subcutaneous injection 
(Doerge et al., 2002; Jefferson et al., 2009). Comparable genistin and GEN doses administered 
through either exposure route resulted in similar estrogenic responses and long term 
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reproductive effects (Jefferson et al., 2009). Furthermore, serum GEN levels in these mice are 
comparable to serum GEN levels in infants fed soy infant formulas (Cao et al., 2009; Jefferson 
et al., 2012). Together these studies indicate that the 50 mg/kg/day GEN dose and 
subcutaneous route of exposure is appropriate to model biologic activity in infants exposed to 
GEN through consumption of soy-based formulas (Jefferson et al., 2009). 
 
Investigating Sine Oculis-related Homeobox 1 Homolog (SIX1) as a Mediator of 
Xenoestrogen-induced Endometrial Cancer 
Despite many studies reporting latent effects of developmental GEN or DES exposures, 
the biological mechanisms driving these pathological changes are unknown. Several studies 
have reported that neonatal xenoestrogen exposure impacts uterine gene expression to 
fundamentally alter developmental patterning of the mouse female reproductive tract (Jefferson 
et al., 2011; Jefferson et al., 2012; Jefferson et al., 2013). In addition, these altered gene 
expression patterns are associated with the development of uterine pathologies and neoplasia 
(Newbold et al., 2007; Jefferson et al., 2011; Jefferson et al., 2012; Jefferson et al., 2013). One 
of the altered proteins is the developmentally important and cancer associated transcription 
factor, sine oculis-related homeobox 1 homolog (SIX1). Following neonatal GEN or DES 
exposure, SIX1 becomes permanently aberrantly expressed in the mouse uterus (Jefferson et 
al., 2011; Jefferson et al., 2013). 
SIX1 is a homeodomain-containing transcription factor that plays essential roles in 
mouse organogenesis and tissue maintenance by regulating cell proliferation, differentiation, 
survival, migration, and invasion (Christensen et al., 2008; Wu et al., 2015). The sine oculis 
homeobox gene family is comprised of six members, all of which have a conserved six domain 
(SD) for protein-protein interactions and a homeodomain (HD) for DNA-binding (Kumar, 2009). 
SIX1 directly and indirectly regulates a diverse network of downstream pathways through 
interaction with cofactors Dachshund (DACH) and eyes absent (EYA) (Kumar, 2009). SIX1 can 
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act as a transcriptional activator or repressor depending on the cofactors present in the complex 
(Li et al., 2003). In general, SIX/EYA/DACH and SIX/EYA complexes function to activate 
transcription whereas the SIX/DACH complex acts as a repressor (Liu et al., 2016). Six1 null 
mice display severe muscle hypoplasia, abnormal bone growth, and lack kidney and inner ear 
development, collectively resulting in perinatal lethality (Laclef et al., 2003). In adult mice, SIX1 
mediates muscle and kidney tissue regeneration through stem cell maintenance and 
differentiation (Swetha et al., 2011; Le Grand et al., 2012). 
Not surprisingly, dysregulation and inappropriate reactivation of SIX1 is observed in 
carcinogenesis. In animal models and in vitro studies, SIX1 induces genomic instability, 
malignant transformation, and metastasis (Christensen et al., 2008; Wu et al., 2015; Blevins et 
al., 2015). SIX1 mediates these processes through direct and indirect regulation of cyclins, v-
myc avian myelocytomatosis viral oncogene homolog (c-Myc), ezrin, tumor growth factor beta 
(TGFβ), and tumor protein 53 (P53) (Christensen et al., 2008; Blevins et al., 2015; Towers et al., 
2015). Aberrant SIX1 expression has been described in several human cancers and has been 
associated with tumor resistance and poor survival (Christensen et al., 2008). Thus far, the 
SIX1/EYA complex is implicated in several hallmarks of cancer including genome instability and 
mutation, resisting cell death, sustaining proliferative signaling, evading growth suppression, 
and activating invasion and metastasis (Hanahan and Weinberg, 2011; Blevins et al., 2015). 
Together these findings, suggest that aberrant uterine SIX1 may play a role in xenoestrogen-
induced endometrial carcinogenesis. 
In the neonatal and adult mouse female reproductive tract, Six1 transcript expression is 
normally restricted to the squamous cells of the cervix and vagina and absent from the glandular 
epithelium of the uterus and oviduct (Jefferson et al., 2011; Jefferson et al., 2013). As described 
previously, exposure to xenoestrogens during female reproductive tract differentiation 
fundamentally alters developmental patterning of the female reproductive tract (Kurita, 2011; 
Jefferson et al., 2011; Cooke et al., 2013). One of the changes observed is a shift in the pattern 
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of Six1 transcript expression from the vagina and cervix to the more anterior regions of the 
female reproductive tract, the uterus and oviduct (Jefferson et al., 2011). Neonatal DES 
exposure results in differential expression of chromatin modifying proteins and permanently 
altered Six1 gene locus-specific epigenetic marks that likely contribute to its abnormal uterine 
expression (Jefferson et al., 2013). Furthermore, neonatal exposure to estrogenic chemicals not 
only causes a dramatic increase in Six1 transcript and protein expression in the mouse uterus, 
but it also causes it to become estrogen-responsive later in life (Jefferson et al., 2011; Jefferson 
et al., 2013). These findings suggest that aberrant uterine expression of SIX1 following neonatal 
GEN or DES exposure may be involved in the endometrial carcinoma phenotype in this mouse 
model. 
 
Scope of the Dissertation 
With a growing body of evidence tying early life exposures to development of adult 
disease, there remains a critical need for understanding how early exposure to estrogenic 
chemicals leads to the pathogenesis of reproductive diseases. Characterizing the molecular 
mechanisms underlying the development of endometrial carcinoma and other histopathologic 
changes resulting from neonatal xenoestrogen exposure will provide a molecular basis for 
understanding the adverse impacts of developmental exposures to xenoestrogens. 
The aim of the research presented in the following chapters was to provide basic 
knowledge about the molecular mechanisms by which exposure to either GEN or DES leads to 
changes in the female reproductive tract culminating in the development of endometrial cancer. 
My overarching hypothesis was that neonatal xenoestrogen exposure establishes permanent 
changes in uterine gene expression, resulting in aberrant cellular reprogramming that leads to 
endometrial carcinogenesis. I hypothesized that persistent up-regulation of SIX1 contributes to 
the endometrial cancer phenotype. To test this hypothesis, I investigated whether permanent 
aberrant expression of SIX1 in the uterus correlates with the development of uterine carcinoma 
13 
in mice neonatally exposed to DES or GEN (Chapter 2), whether SIX1 is present in human 
endometrium and endometrial cancer (Chapter 2), characterized GEN and DES-induced uterine 
pathologies over the course of pathogenesis (Chapter 3), and whether SIX1 is necessary or 
sufficient for the development of uterine carcinogenesis using genetic mouse models (Chapter 
4). 
In this dissertation, I provide compelling evidence that GEN- or DES-exposure induced 
SIX1 expression is a biomarker for xenoestrogen exposure and for disease development. I 
identified SIX1 in a potential cancer progenitor cell population in this mouse model and found 
that it contributes to abnormal endometrial epithelial differentiation. Furthermore, I showed that 
SIX1 was present in human endometrial cancer. Although my findings suggest that SIX1 is not 
required for xenoestrogen-induced carcinogenesis and that SIX1 is not able to induce cancer 
independent of xenoestrogen exposure, I demonstrated that it is an important biomarker and 
could be used for further investigation of the proposed cancer progenitor cell population. 
Findings from my research may be extended to establish a toxicity pathway from developmental 
exposure to estrogenic chemicals to permanent epigenetic alterations and cellular changes that 
lead to abnormal endometrial epithelial differentiation. Characterization of SIX1 as a biomarker 
in xenoestrogen-induced uterine carcinogenesis and in human endometrial cancer may provide 
utility in cancer screening, inform pharmacological strategies for treatment, and provide 
mechanistic information for future risk assessments of environmentally-relevant estrogenic 
chemicals. 
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CHAPTER 2 – SIX1 ONCOPROTEIN AS A BIOMARKER IN A MODEL OF HORMONAL 
CARCINOGENESIS AND IN HUMAN ENDOMETRIAL CANCER 
 
Introduction 
As described in Chapter 1, SIX1 becomes aberrantly expressed in the uteri of mice 
exposed neonatally to GEN or DES, likely as a result of permanent alterations in Six1 gene 
locus-specific epigenetic marks that are established during exposure (Jefferson et al., 2011; 
Jefferson et al., 2013). The role of SIX1 in tissue development and its implication in cancer 
indicates that it may be involved in mediating xenoestrogen-induced endometrial cancer. 
Here we evaluated endometrial SIX1 expression during the development of endometrial 
carcinoma in mice following neonatal GEN or DES exposure. SIX1 expression following both 
exposures was highly associated with endometrial carcinoma development and SIX1 was 
prominently expressed in an abnormal basal cell population and all preneoplastic and neoplastic 
lesions. We also surveyed a large number of human endometrial cancer tissues for the 
presence of SIX1 to determine whether it might contribute to endometrial cancer 
pathophysiology in women. SIX1 was expressed in a subset of human endometrial cancer 
patients who were more likely to have late-stage disease. These findings indicate that SIX1 
expression may serve as a useful biomarker of endometrial carcinogenesis. 
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Materials and Methods 
Animals 
Care and use of animals complied with the NIEHS/NIH animal care guidelines and 
followed an approved institutional animal care and use protocol. The xenoestrogen exposure 
model has been described previously (Jefferson et al., 2011; Jefferson et al., 2013). Key details 
include daily subcutaneous injection (0.02 mL) of female CD-1 pups beginning on the day of 
birth (postnatal day 1 [PND1]) through PND5 with vehicle alone (corn oil), genistein (GEN; 50 
mg/kg/day), or diethylstilbestrol (DES; 1 mg/kg/day). To test if SIX1 expression is associated 
with cancer development, sample sizes were calculated based on 1) previously published 
studies showing that 35% of neonatally GEN-exposed CD-1 mice and 90% of neonatally DES-
exposed CD-1 mice develop cancer by 18 months of age and 2) pilot data showing that 0% of 
CON mice and 100% of mice exposed neonatally to GEN or DES showed uterine SIX1 
expression (Newbold et al., 1990; Newbold et al., 2001; Jefferson et al., 2011; Jefferson et al., 
2013). We estimated that using 26 mice per exposure group would allow us to detect a 25% 
difference in cancer incidence (one-sided 0.05 level of significance with 80% power) beginning 
at 6 months of age, as well as allow us to detect a difference in SIX1 expression. 
Mice were euthanized by CO2 asphyxiation at their respective endpoints and the 
reproductive tracts were collected. A cranial segment of the right uterine horn was removed, 
snap-frozen on dry ice, and stored at -80°C until use. The remaining female reproductive tract 
was formalin-fixed, processed using standard histologic procedures, sectioned longitudinally at 
6 µm, and stained with hematoxylin and eosin (H&E) or left unstained for 
immunohistochemistry.  
Human Endometrial Tissue Samples 
After receiving Institutional Review Board (IRB) approval, women undergoing 
hysterectomy for endometrial hyperplasia, endometrial cancer, and benign indications were 
identified, and their hysterectomy specimens obtained from the University of North Carolina at 
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Chapel Hill (UNC Chapel Hill) Department of Pathology and Laboratory Medicine. Tissue 
microarrays (TMAs) were constructed from the formalin-fixed, paraffin-embedded hysterectomy 
specimens. Additional endometrial TMAs were purchased from a commercial vendor (U.S. 
Biomax, Inc., Rockville, MD; TMA UT501, UT801, UT803, UT1501, EMC1021). All TMA 
specimens were obtained with informed consent according to U.S. federal law. Patient 
diagnoses and pathological descriptions were provided with the TMAs. For comparison, TNM 
scores were converted to FIGO stage based on previously described guidelines (Creasman, 
2015). Serial sections of TMAs were freshly cut for immunohistochemical (IHC) staining. 
Mouse and Human Immunohistochemistry 
Serial sections of mouse female reproductive tract or human endometrial TMAs were 
deparaffinized in xylene and rehydrated with gradient ethanol. Heat-induced epitope retrieval 
was performed using respective antigen retrieval solutions (SIX1, Ki67: citrate buffer, pH 6.0; 
K18: Nuclear Decloaker, pH 9.5, Biocare, Concord, CA) in the Decloaker® pressure chamber 
for 5 minutes at 120°C, followed by 3% H2O2 for 15 minutes to quench endogenous peroxidase 
activity. Non-specific binding was blocked using respective blocking solutions and serum (SIX1: 
Avidin/biotin blocking kit, Vector, Burlingame, CA, with 10% donkey serum, Jackson 
Immunoresearch, West Grove, PA; Ki67: Rodent Block M, Biocare; Keratin 18, type I (K18): 
Avidin/biotin blocking kit, Vector, with 10% horse serum, Jackson Immunoresearch). Sections 
were incubated with respective primary and secondary antibodies (SIX1: 0.2-0.4 µg/ml anti-SIX1 
antibody, HPA001893, Sigma-Aldrich, St. Louis, MO, and 2.2 µg/ml biotinylated donkey anti-
rabbit IgG, Jackson Immunoresearch; Ki67: 1.1 µg/ml anti-Ki-67 antibody, CRM325C, Biocare; 
K18: 8 µg/ml anti-cytokeratin 18 antibody, sc-51582, Santa Cruz, Dallas, TX, and 0.5 µg/ml 
biotinylated horse anti-mouse IgG, Vector) and visualized using respective detection systems 
(SIX1 and K18: Vectastain Elite ABC R.T.U. label, Vector) and 3,3-diaminobenzidine, Dako, 
Carpinteria, CA; Ki67: Rabbit on Rodent HRP Polymer, Biocare, and 3,3-diaminobenzidine, 
Dako). Slides were counterstained with hematoxylin. Mouse sections were stained using the 
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Intellipath FLX autostainer (Biocare). Human endometrial TMAs were stained manually. 
Appropriate positive and negative control tissues were stained for all IHC experiments. 
Mouse Histopathologic Analysis 
A single H&E section of the female reproductive tract including uterine horns/body, 
cervix, and anterior vaginal canal was evaluated for each mouse via light microscopy by a 
certified study pathologist. Histopathologic diagnoses were based on standard criteria and 
nomenclature for nonneoplastic and neoplastic lesions (Newbold et al., 1990; Dixon et al., 
2014). Images were captured using a Lumenera Infinity 2-3C digital camera (Ottawa, Ontario). 
Mouse and Human Immunohistochemical Analysis 
Mouse female reproductive tract sections were stained for SIX1 and the proliferation-
related Ki67 antigen (Ki67). Overall abundance of SIX1 labeling was evaluated by light 
microscopy and assigned a qualitative labeling score from 0 to 4 (0, absent; 1, minimal; 2, mild; 
3, moderate; 4, severe) based on staining intensity and the estimated percentage of labeled 
cells within a section. Lesion-specific localization of SIX1 labeling was confirmed as needed by 
comparison with corresponding adjacent H&E-stained sections. 
Human TMA serial sections were stained for SIX1 and K18 and evaluated by a certified 
pathologist blinded to all clinical and pathological information. Core biopsy sections lacking 
epithelium (confirmed by absence of K18 staining) were unable to be evaluated and removed 
from the study. For core biopsy sections containing epithelial tissue, SIX1 staining was 
categorized as positive or negative based on the presence of brown labeling in at least 1% of 
epithelial nuclei. Nuclear labeling that was low intensity but readily discernible at 20x objective 
magnification and clearly distinguished from nearby unlabeled nuclei was called positive. A 
limited number of sections had weak cytoplasmic staining for SIX1 diffusely or along tissue 
edges, which was considered background. Cytoplasmic or nuclear staining of non-epithelial “off-
target” cells (myometrial, stromal, or immune) observed in a subset of sections was not 
considered in SIX1 classification, which was based strictly on nuclear staining in epithelial cells.  
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Approximately 10% of core biopsies (63/643) had equivocal SIX1 labeling that could not 
be clearly identified as positive or negative. Equivocal SIX1 labeled cores presented with weak, 
light brown nuclear speckling in epithelial cells. As a result, 20 patients with only equivocal core 
biopsies were removed from analysis, leaving 369 patients with clearly identifiable core staining. 
Real time RT-PCR 
Total RNA was extracted from whole tissue homogenate of uterine horns and real-time 
RT-PCR was performed using Six1 primers and normalized to cyclophilin A (Ppia) as previously 
described (Jefferson et al., 2013). Expression levels were calculated using the delta Ct method 
(Jefferson et al., 2013; Pfaffl, 2001). 
Immunoblots 
Following the manufacturer’s instructions, nuclear protein was extracted from whole 
uterine tissue using the NE-PER nuclear and cytoplasmic extraction kit and protein 
concentration was measured using the BCA kit (Thermo Scientific, Rockford, IL). Nuclear 
proteins (10 µg) were separated on Novex 16% Tris-glycine gels and transferred to PVDF 
membrane (Invitrogen, Carlsbad, CA). Blots were blocked with 5% milk in Tris-buffered saline 
containing 0.1% Tween-20 (TBST) and then incubated overnight at 4°C with 0.2 µg/ml anti-SIX1 
antibody (HPA001893, Sigma-Aldrich) or 2 ng/ml anti-β-actin antibody (A1978, Sigma-Aldrich) 
in 5% milk in TBST and followed by application of the appropriate secondary antibody. Blots 
were incubated with SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific) 
and then exposed to film. Blots were scanned using the HP Scanjet 7650 (Hewlett-Packard, 
Palo Alto, CA). Images were desaturated in Adobe Photoshop Elements (Adobe, San Jose, CA) 
to remove color without altering the brightness value of the pixels. 
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism, version 5.0c (La Jolla, CA). 
Data were analyzed using 2-way ANOVA, one- or two-tailed Fisher exact test, or Chi-square 
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test, and appropriate post hoc tests for multiple comparisons. Tests used are indicated in Figure 
Legends. Error bars show the standard error of the mean (SEM) for all graphs.  
 
Results 
Progression of SIX1-labeled endometrial cells following neonatal GEN or DES exposure 
We previously reported that in untreated mice on PND1 through adulthood, Six1 
transcripts are expressed in the vagina and cervix but not in the uterine body/horn or oviduct 
(Jefferson et al., 2011). To determine where SIX1 protein normally localizes along the female 
reproductive tract in adult mice, we performed SIX1 IHC at 6, 12, or 18 months of age. 
Consistent with the previously observed transcript expression differences (Jefferson et al., 
2011), there were distinct cell-type specific differences in SIX1 expression (Fig. 2-1A). In the 
vaginal and cervical epithelium, SIX1 localized to the stratified squamous epithelium, with 
highest expression in the basal and suprabasal layers. In the endocervix, nuclear SIX1 labeling 
was observed in simple columnar glandular epithelial cells only when there was a layer of basal 
cells directly subjacent to the luminal cells. SIX1 expression was not observed in endometrial 
luminal epithelium or morphologically normal glands (Fig. 2-1A; Table 2-1). SIX1 was present in 
the uteri of a few control mice but was limited to small focal areas of squamous metaplasia in 
the uterine body (Table 2-1). 
Following a 5-day neonatal exposure to GEN or DES, uterine Six1 transcript expression 
is increased at PND5, PND22, and 2 months of age, when there is also a dramatic increase in 
SIX1 protein expression in the uterus (Jefferson et al., 2011; Jefferson et al., 2013). To assess 
SIX1 localization during its initial appearance and progression, we performed SIX1 IHC on uteri 
collected on the final day of treatment (PND5) and at 6 months of age, when endometrial 
carcinoma was first observed. In controls, SIX1 was not present at either PND5 or in the vast 
majority of mice at 6 months of age (Fig. 2-1B). In both neonatally GEN- and DES-exposed 
groups, nuclear SIX1 labeling was present in low numbers of scattered luminal and basal-type 
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epithelial cells on PND5 (Fig. 2-1B). In some cases, these SIX1-labeled cells appeared to be 
traversing the basement membrane. Uteri from GEN- and DES-exposed mice on PND5 
exhibited classical responses to estrogen similar to those previously reported, including 
increased columnar cell height, an overall increase in cellularity, and edema (Yoshida et al., 
1999). However, there was no evidence of basal cell metaplasia, squamous metaplasia, or 
other proliferative lesions at PND5. At 6 months of age, SIX1 localized to basal cell and 
squamous metaplasia in nonneoplastic endometrial glands of most mice neonatally exposed to 
GEN or DES (Fig. 2-1B, Table 2-1). SIX1 labeling was often present in a patchy or “hot spot” 
distribution (i.e. abundantly expressed throughout a given metaplastic gland but not in 
surrounding glands), suggesting a differentiation-specific expression pattern that may have 
developed from scattered SIX1-labeled founder cells present in early development. SIX1 was 
most prominent in glands with basal-type cells underlying luminal columnar cells. These findings 
indicated that endometrial SIX1 expression and epithelial morphology was permanently altered 
following neonatal exposure to GEN or DES. 
Reproductive tract changes resulting from neonatal GEN or DES exposure 
To determine how SIX1 expression correlated with uterine histopathological changes, 
we first characterized the reproductive tract changes at 6, 12, and 18 months of age. Neonatal 
exposure to either GEN or DES resulted in histopathological changes consistent with previous 
reports in this model (Newbold et al., 1990; Newbold et al., 2001). Neonatal exposure to GEN or 
DES resulted in a similar spectrum of nonneoplastic uterine abnormalities, including cystic 
change, adenomyosis, squamous metaplasia, and basal cell metaplasia. Atypical hyperplasia 
and carcinomas of endometrial glands were also observed in these groups. Detailed 
descriptions and representative images of these diagnoses are included in Chapter 3. All of 
these histopathological findings increased with age in GEN- or DES-exposed groups and had a 
significantly higher incidence compared to control mice by 18 months of age (Table 2-1). There 
was also a low incidence of vaginal adenosis in DES-treated mice at each time point. 
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Basal cell metaplasia was a prominent feature in the endometrium of GEN- or DES-
exposed mice at all time points. This change was characterized by the presence of cuboidal 
basal epithelial cells underlying columnar glandular epithelial cells (beyond the endocervix), 
which gave these endometrial glands a distinctive bilaminar appearance. Basal cell metaplasia 
was distinguished from squamous metaplasia by the lack of a clear maturation lineage of 
stratified squamous cells but appeared to be the morphologic precursor of squamous 
metaplasia. Notably, both basal cell and squamous metaplasia were prominent features of 
atypical hyperplasias and carcinomas in GEN- or DES-exposed mice. Previously, these 
neoplastic lesions were diagnosed as adenocarcinomas because neoplastic cells consistently 
form rudimentary gland-like structures with central lumens (Newbold et al., 1990; Newbold et al., 
2001). However, these cancers often showed pleomorphic differentiation patterns, including 
distinct squamous-like features and, less commonly, mucous cell populations. According to 
current nomenclature, a subset of more squamous neoplastic lesions would qualify as 
adenosquamous carcinomas. 
Uterine SIX1 expression is associated with development of endometrial carcinoma and localized 
to neoplastic lesions 
To investigate if SIX1 expression correlated with increasing cancer incidence in mice 
neonatally exposed to GEN or DES, we measured Six1 transcript levels by quantitative PCR at 
6, 12, and 18 months of age, and confirmed protein expression by immunoblot at 6 months of 
age. Endometrial carcinomas were not observed in control mice at any time point, while marked 
increases in carcinoma incidence were observed in GEN- or DES-exposed groups at 12 and 18 
months of age (Fig. 2-2A; Table 2-1). Consistent with previously described results, uteri from 
control mice expressed low levels of Six1 transcript at all time points (Jefferson et al., 2013), 
likely due to normal expression in the myometrium (El-Hashash et al., 2011; Wu et al., 2015). 
Six1 transcript levels increased with age in GEN- or DES-exposed groups, with >9-fold 
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increases at 18 months of age (Fig. 2-2B). Uterine SIX1 protein expression was also observed 
in mice exposed neonatally to GEN or DES but not in control mice (Fig. 2-2C). 
We next evaluated SIX1 protein localization over time in GEN- or DES-exposed mice. By 
18 months of age, all mice neonatally exposed to GEN or DES had SIX1 labeling specifically 
within nonneoplastic glands that exhibited basal cell or squamous metaplasia (Table 2-1). SIX1 
expression was present in both basal and luminal cells; however, luminal expression was 
typically present only when there were subjacent SIX1-labeled basal cells. All hyperplastic and 
neoplastic lesions showed positive nuclear labeling for SIX1, which was present in areas of 
glandular, basal cell, and squamous differentiation (Fig. 2-2D, Table 2-1). In sum, SIX1 
expression localized to regions of abnormal differentiation (metaplastic basal cells), luminal cells 
adjacent to aberrant basal cells, hyperplastic lesions, and carcinomas, findings that are 
consistent with a role for SIX1 in malignant transformation. 
SIX1 is expressed in human endometrial cancers and correlates with late-stage cancer 
SIX1 overexpression is observed in a number of primary human cancers, where it is 
associated with recurrence, metastasis, resistance to standard chemotherapeutic agents, and 
decreased patient survival (Iwanaga et al., 2012; Li et al., 2013a; Towers et al., 2015; Zeng et 
al., 2015; Blevins et al., 2015; Wu et al., 2015; Armat et al., 2016). Our findings in the mouse 
suggested that aberrant SIX1 expression could have a role in human endometrial cancer, but to 
date there are no published reports that have addressed this question. To test if SIX1 
expression is a feature of human endometrial cancers, we evaluated SIX1 labeling in human 
endometrial tissue microarrays containing biopsies from patients with normal, pathologically 
abnormal but nonneoplastic, preneoplastic, and neoplastic endometrial tissue (Fig. 2-3; Table 2-
2). A total of 580 core biopsies from 369 patients (1-4 core biopsies per patient) were evaluated. 
All patients had at least one core containing glandular epithelium identifiable by morphology and 
K18 labeling. Patients with at least one core biopsy with SIX1 labeling were considered SIX1-
positive patients; an example is shown in Figure 2-3A. Patients lacking SIX1 labeling in all of 
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their core biopsies were considered SIX1-negative patients. Twenty-two percent (81/369) of 
patients were classified as SIX1-positive (Table 2-2). Of the 81 SIX1-positive patients, 63 had 
100% SIX1 positive cores and 18 had 50-75% SIX1 positive cores. These findings indicate that 
patients with fewer core biopsies were not more likely to be falsely assigned as SIX1-negative. 
SIX1 labeling was generally low-intensity with pockets of moderate- to high-intensity positive 
cells. SIX1 labeling was only detected in preneoplastic and neoplastic tissue from endometrial 
cancer patients and was not observed in any other types of endometrial tissue (Fig. 2-3B; Table 
2-2). SIX1 labeling was not specific to a particular morphologic subtype of endometrial cancer 
analyzed (Table 2-2). There was no difference in average age or BMI between SIX1-positive 
and SIX1-negative patients (data not shown). Together, these data indicate that SIX1 
expression is specific to a molecular subset of endometrial cancers. 
To test if SIX1 expression was associated with cancer progression and metastasis, we 
grouped cancer patients by grade and stage. Cancer grade, ranging from grade 1-3 (G1-3), was 
provided for 277/299 endometrial cancer patients (79/80 SIX1-positive and 198/219 SIX1-
negative patients). When cancer patients were grouped by their defined grade, the percentage 
of cancer patients with SIX1 labeling was similar between cancer grades (Fig. 2-3C). Cancer 
stage information was provided for 282/299 endometrial cancer patients (78/80 SIX1-positive 
and 204/219 SIX1-negative patients). SIX1-positive cancer patients with defined stages were 
separated into two stage categories for analysis, early-stage (I-II) and late-stage (III-IV), 
because there were few patients with either stage II or IV cancers. The percentage of cancer 
patients with SIX1 labeling was higher in late-stage as compared to early-stage patients (Fig. 2-
3D). These findings suggest that patients with SIX1-positive cancers were also more likely to 
have late-stage disease. 
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Discussion 
Here we demonstrated that neonatally exposing mice to GEN or DES induces 
permanent uterine expression of the oncofetal protein SIX1. Transcript and protein levels of 
SIX1 increased with age and were associated with endometrial carcinoma incidence. SIX1 
expression was localized to an abnormal population of basal epithelial cells within metaplastic 
endometrial glands and to glandular, basal, and squamous cells within all endometrial 
hyperplastic lesions and carcinomas. These findings indicate that neonatal estrogenic chemical 
exposure initiates aberrant expression of SIX1 within the endometrium, which over time may 
promote malignant transformation.  
Previous work indicates that neonatal exposure to an estrogenic chemical alone does 
not cause uterine cancer in this mouse model; instead, subsequent exposure to ovarian 
hormones is required (Leavitt et al., 1981; Newbold et al., 1990). These findings indicate that 
endogenous ovarian hormones secreted following puberty play an essential role in cancer 
development, likely a result of estrogen action (Leavitt et al., 1981; Ostrander et al., 1985). We 
previously showed that pre-treatment with an ER antagonist blocks neonatal GEN-induced Six1 
transcript expression (Jefferson et al., 2011). Additionally, exposing adult control mice to 
estradiol or DES does not induce uterine Six1 transcript expression (Jefferson et al., 2013). 
Taken together, these data suggest that neonatal xenoestrogen exposure induces SIX1 
expression and reprograms Six1 to be responsive to later estrogen exposure. This estrogen 
sensitivity is likely mediated by epigenetic changes induced by neonatal estrogen exposure at 
the Six1 gene locus (Jefferson et al., 2013). The timeline of SIX1 expression and cancer 
development thus fits with a multi-hit cancer hypothesis.  
To explain neonatal xenoestrogen-induced malignant transformation of the 
endometrium, we propose a model outlining the developmental origins and progression of 
hormonal carcinogenesis (Fig. 2-4). A critical component of the model is that exposure during a 
sensitive developmental period is essential to establish aberrant constitutive expression of SIX1 
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and serves as a molecular initiating event. Neonatal xenoestrogen exposure initiates aberrant 
SIX1 expression in cells that continue to express SIX1 as a result of positive autoregulation 
(Sato et al., 2012; Grifone et al., 2005). Persistent SIX1 expression causes the establishment of 
a basal cell population that gives the endometrial epithelium a distinct bilaminar morphology. 
SIX1 localization in luminal cells appears to be dependent upon the abnormal presence of 
underlying SIX1-labeled basal cells, suggesting the basal cells either differentiate into SIX1-
labeled luminal cells or facilitate luminal SIX1 expression via cell-to-cell communication. 
Subsequent cyclic exposure to endogenous estrogen, beginning at puberty, promotes SIX1 
expression in these cells through its acquired estrogen responsiveness. SIX1 then causes 
proliferation of the basal cells through its effects on cell cycle-regulatory proteins and resistance 
to apoptosis (Towers et al., 2015; Armat et al., 2016; Yu et al., 2006; Li et al., 2013a; Coletta et 
al., 2004). These cells can undergo further transformation (Coletta et al., 2008; McCoy et al., 
2009; Micalizzi et al., 2009; Ono et al., 2012; Radisky, 2009; Wang et al., 2012; Zeng et al., 
2016; Cieply et al., 2013). This neoplastic process occurs specifically in the endometrial 
epithelium, which lacks normal location-specific growth restraints that may be present in the 
stratified squamous epithelium of the lower reproductive tract. Future studies are needed to 
investigate factors that drive malignant transformation specifically in the endometrium but not in 
other sites like cervical and vaginal epithelium, where SIX1 is expressed but does not promote 
cancer in the neonatal mouse model. 
Recent studies across different cancer types have implicated SIX1 in several key 
carcinogenic processes. These hallmarks include sustained proliferative cell signaling, invasion 
and metastasis, evasion of growth suppressors, induction of genomic instability, and resistance 
to cell death (Blevins et al., 2015; Hanahan and Weinberg, 2011). In pancreatic, 
rhabdomyosarcoma, and breast cancer cell lines, SIX1 modulates cell cycle progression by 
direct transcriptional regulation of cyclins (Yu et al., 2006; Li et al., 2013b; Coletta et al., 2004). 
SIX1 also indirectly downregulates P53 in breast cancer cell lines (Towers et al., 2015). 
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Furthermore, mammary gland-specific SIX1 overexpression in a transgenic mouse model 
induces mammary gland tumors (McCoy et al., 2009). The potential pleiotropic roles of SIX1 in 
the uterus following neonatal estrogenic chemical exposure are unknown, but SIX1 binding 
partners, including EYA 1-4, DACH 1 and 2, and CREB binding protein, are expressed in the 
mouse female reproductive tract based on microarray data, suggesting that SIX1 is regulating 
transcriptional activity in the uterus (Jefferson et al., 2011; Blevins et al., 2015). Determining if 
SIX1 is necessary or sufficient for endometrial carcinoma development will require additional 
studies using mouse genetic models. 
We showed that SIX1 was expressed in a subset of human endometrial cancers, 
suggesting that this biomarker may define a molecular subtype. A similar incidence of aberrant 
upregulated SIX1 expression has been reported in cervix cancer (Wan et al., 2008). We found 
that SIX1 was not differentially expressed in endometrial cancers based on their specific 
histological classifications, similar to previous observations in breast and cervix cancers 
(Iwanaga et al., 2012; Zheng et al., 2010). Because SIX1 overexpression in human endometrial 
and other cancers may represent a loss of differentiation or reversion to a developmental 
phenotype, SIX1 may be acting as an oncofetal protein (Li et al., 2013b; Coletta et al., 2004). 
The diverse morphologic features represented in neoplastic endometrial glands in our mouse 
model, which included glandular, squamous, and mucous cell differentiation, support this idea. 
Similarly, histologically diverse neoplastic lesions were observed in a mouse model of mammary 
gland-specific transgenic SIX1 expression (McCoy et al., 2009), suggesting multipotency of 
aberrant SIX1-labeled cells. We did not observe a correlation between SIX1 expression and 
cancer grade, which has been observed in previous studies of prostate cancer (Zeng et al., 
2015), but did find that SIX1 was expressed more often in endometrial cancers from patients 
with later stage disease. This finding is consistent with studies showing that SIX1 expression 
correlates with advanced cancer stage in prostate, ovarian, cervix, and breast cancers (Zeng et 
al., 2015; Wan et al., 2008; Behbakht et al., 2007; Reichenberger et al., 2005) and with effects 
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of SIX1 in promoting cell migration, invasion, and metastasis by upregulating pro-tumorigenic 
genes including tumor growth factor beta, vascular endothelial growth factor-c, and ezrin 
(Iwanaga et al., 2012; Yu et al., 2006; Micalizzi et al., 2009; Wang et al., 2012).  
Findings from this study indicate that in a mouse model of hormonal carcinogenesis, 
exposure to xenoestrogens during a key period of reproductive tract cell differentiation results in 
the establishment of a new cell type within the endometrial glands that aberrantly expresses 
SIX1 and is associated with endometrial carcinoma development. Additionally, SIX1 is 
specifically expressed in a subset of human endometrial cancers.  Together, these findings 
indicate that SIX1 may play a role in endometrial carcinogenesis in mice and women and that 
SIX1 may serve as a biomarker of aberrant response to estrogen and a molecular subtype of 
endometrial cancer. 
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Table 2-1 Incidence of reproductive tract abnormalities and SIX1 expression in mice exposed neonatally to 
GEN or DES1 
     Age (months)2   
    6   12   18 
Site Pathology  CON GEN DES   CON GEN DES   CON GEN DES 
Vagina Adenosis  0/33 (0%) 0/30 (0%)  2/31 (6%)   0/29 (0%) 0/30 (0%) 2/26 (8%)   0/30 (0%) 1/30 (3%) 2/30 (7%) 
Uterus Cystic change  2/33 (6%) 12/30* (40%) 4/31 (13%)   7/29 (24%) 23/30* (77%) 10/26 (38%)   15/30 (50%) 27/30* (90%) 23/30 (77%) 
 Adenomyosis  0/33 (0%) 6/30* (20%) 13/31* (42%)   3/29 (10%) 10/30 (33%) 13/26* (50%)   4/30 (13%) 13/30* (43%) 18/30* (60%) 
 Basal cell 
metaplasia  3/33 (9%) 19/30* (63%) 30/31* (97%)  2/29 (7%) 26/30* (87%) 25/26* (96%)  0/30 (0%) 30/30* (100%) 29/30* (97%) 
 Squamous 
metaplasia3  1/33 (3%) 11/30* (37%) 7/31* (23%)   0/29 (0%) 16/30* (53%) 12/26* (46%)   0/30  (0%) 24/30* (80%) 14/30* (47%) 
 Atypical 
hyperplasia  0/33 (0%) 3/30 (10%) 14/31* (45%)   0/29 (0%) 9/30* (30%) 14/26* (54%)   0/30 (0%) 15/30* (50%) 18/30* (60%) 
 Carcinoma  0/33 (0%) 2/30 (7%) 5/31 (16%)   0/29 (0%) 7/30* (23%) 9/26* (35%)   0/30 (0%) 10/30* (33%) 12/30* (40%) 
 Sarcoma  0/33 (0%) 0/30 (0%) 1/31 (3%)  0/29 (0%) 1/30 (3%) 0/26 (0%)  0/30 (0%) 2/30 (7%) 0/30 (0%) 
SIX1 IHC                
Vagina Epithelium4  33/33 (100%) 30/30 (100%) 31/31 (100%)  29/29 (100%) 30/30 (100%) 26/26 (100%)  30/30 (100%) 30/30 (100%) 30/30 (100%) 
 Labeling index5  2.2 1.8 1.5   1.6 1.1 1.2   1.9 1.7 1.7 
Uterus Nonneoplastic epithelium6  3/33 (9%) 21/30* (70%) 30/31* (97%)   2/29 (7%) 26/30* (87%) 25/26* (96%)   0/30 (0%) 30/30* (100%) 30/30* (100%) 
 Labeling index5  0.1 0.9 1.5   0.1 1.5 2.0   0.0 2.0 2.6 
 Neoplastic 
epithelium7  NA 2/2 (100%) 5/5 (100%)  NA 7/7 (100%) 9/9 (100%)  NA 10/10 (100%) 12/12 (100%) 
 Labeling index5  NA 2.5 2.8  NA 2.0 2.7  NA 2.1 2.4 
Abbreviations: CON, control; GEN, genistein; DES, diethylstilbestrol; NA, not applicable 
*Significant using one-tailed Fisher exact test P<0.05 compared to corresponding age-matched CON mice 
n=26-33 mice per exposure and age group as indicated in the table 
1Mice were given injections of GEN (50 mg/kg/day) or DES (1 mg/kg/day) on days 1-5 of neonatal life 
2Mice were necropsied at indicated ages 
3Stratified squamous cells replacing glandular epithelium; distinct from a single layer of basal cells 
4Predominantly basal and suprabasal cells 
5Average qualitative labeling score from 0 to 4 for SIX1 across the group 
6Number of animals with SIX1 labeling out of all animals within that group 
7Number of animals with SIX1 labeling in neoplastic lesions out of animals with carcinoma 
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Table 2-2 Incidence of human endometrial SIX1 expression in patients with different 
histopathologic diagnoses 
Patient  
Diagnosis  Histology  # Patients  # SIX1 Positive  # SIX1 Negative  % SIX1 Positive 
Normal  Normal  28  0  28  0% 
Nonneoplastic  Normal cancer-adjacent  13  0  13  0% 
   Hyperplasia  21  0  21  0% 
   Inflammation  5  0  5  0% 
Preneoplastic  Atypical hyperplasia  3  1  2  33% 
Neoplastic  Endometrioid adenocarcinoma  171  43  128  25% 
   Unspecified adenocarcinoma  87  28  59  32% 
   Serous carcinoma  11  4  7  36% 
   Clear cell carcinoma  4  0  4  0% 
   Mucinous carcinoma  1  1  0  100% 
   Adenocarcinoma metastasis  5  0  5  0% 
   Adenosquamous carcinoma  7  1  6  14% 
   Squamous carcinoma  8  3  5  38% 
   Undifferentiated carcinoma  2  0  2  0% 
   Stromal sarcoma  1  0  1  0% 
   Chorionic carcinoma  2  0  2  0% 
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Figure 2-1 SIX1 localization in controls and following neonatal estrogenic chemical 
exposure. A. Representative SIX1 labeling in a control adult female mouse reproductive tract at 
6 months of age. Arrowhead indicates squamocolumnar junction (SCJ). B. Appearance and 
expansion of SIX1 labeled cells in mouse endometrium following neonatal GEN or DES 
exposure at PND5 or 6 months of age. Arrowhead indicates SIX1-labeled columnar cells and 
asterisk indicates SIX1-labled basal-type cells underlying the glandular epithelium. Arrow 
indicates large SIX1-labeled basal-type cell that appears to be traversing the basement 
membrane. Representative images were taken at an objective magnification of 60x (PND 5) or 
40x (6 months of age). 
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Figure 2-2 Association between development of endometrial carcinoma and SIX1 
expression in mice neonatally exposed to GEN or DES. Figure legend continues on the 
following page. 
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Figure 2-2 Association between development of endometrial carcinoma and SIX1 
expression in mice neonatally exposed to GEN or DES. A. Incidence of endometrial 
carcinoma over time in aged CON, GEN, or DES groups. n=26-31 mice per exposure and age 
group. One-tailed Fisher exact test: *, P<0.05 compared to corresponding age-matched CON 
group. B. Six1 transcript expression in aged CON, GEN, and DES groups. n=27-33 mice per 
treatment and age group; mean ± S.E.M. is plotted. Two-way ANOVA with Tukey test for 
multiple comparison (a-d): P=0.0001. C. SIX1 immunoblotting of whole uterine horn tissue from 
two individual CON, GEN, and DES mice at 6 months of age; protein from one mouse per lane; 
n=4 mice per group in two blots. D. SIX1 labeling in endometrial carcinoma lesions from 
neonatally GEN- or DES-exposed mice at 18 months of age. Normal endometrium from CON 
mouse at 18 months of age shown for comparison. Images were taken at an objective 
magnification of 40x. 
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Figure 2-3 SIX1 labeling in human endometrial cancers. A. Normal endometrial tissue (left) 
and endometrial carcinoma (right). Images were taken at an objective magnification of 40x. B. 
Percentage of patients with SIX1 labeling; n=28 normal patients and n=299 cancer patients. 
Two-tailed Fisher exact test: *, P=0.0025. C and D. Percentage of patients with SIX1 labeling 
separated by C, grade; n=24/84 for G1, n=27/110 for G2, and n=28/83 for G3 and D, stage; 
n=59/248 for early and n=19/34 for late. Two-tailed Fisher exact test: *, P=0.0003. 
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Figure 2-4 Multi-hit model outlining the developmental origins and progression of 
estrogen-induced hormonal carcinogenesis. The model is described in detail in the text. 
Blue nuclei indicate cells that do not express SIX1 and brown nuclei indicate cells that express 
SIX1. 
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CHAPTER 3 – DIFFERENTIATION PATTERNS OF XENOESTROGEN-INDUCED 
ENDOMETRIAL CARCINOMA AND ASSOCIATED PRECURSOR LESIONS 
 
Introduction 
The mouse model of neonatal xenoestrogen exposure has been widely studied as a 
classical example of developmental reprogramming in females, in which a shift in differentiation 
patterns early in life permanently alters physiological responses and increases disease risk in 
adulthood. Despite continued interest in this model, many of the basic biological processes 
driving later-life effects of developmental xenoestrogen exposure are still largely unknown. As 
described previously, the neonatal window in mice corresponds with key periods of cellular 
differentiation in the female reproductive tract. Neonatal exposure to xenoestrogens such as 
GEN and DES results in high incidence of endometrial carcinoma by 18 months of age, as well 
as other uterine pathological changes including cystic change, adenomyosis, basal cell and 
squamous metaplasia, and atypical hyperplasia of the endometrial glands, which increase with 
age (Newbold et al., 1990; Newbold et al., 2001; Suen et al., 2016). Prior work has shown that 
endogenous estrogens play an essential role in development of these lesions, which are 
prevented by ovariectomy prior to puberty and global knockout of estrogen receptor alpha 
(ERα), but it remains unclear what pathways are mediating these promotional effects of 
estrogen (Newbold et al., 1990; Ostrander et al., 1985; Leavitt et al., 1981; Couse et al., 2001).  
In Chapter 2, we observed a distinct population of basal cells that arises in the uterus at 
the time of neonatal estrogenic chemical treatment, expands with age, and tracks with 
development of neoplastic lesions. The early appearance of this abnormal cell population 
suggests that neonatal xenoestrogen exposure induces aberrant differentiation of epithelial cells 
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in the developing uterus that potentially act as a cancer progenitor cell population. These cells 
strongly express ERα and basal cell markers, but to date there has not been a detailed 
histopathologic and immunohistochemical characterization of their phenotype before and after 
development of neoplastic lesions. 
Here, we evaluated changes in uterine gland lesions of mice exposed neontally to GEN 
or DES at two time points, in early adulthood prior preneoplastic or neoplastic changes (3 
months of age) and later in life following development of carcinomas (18 months of age). Our 
goal was to document uterine gland differentiation and cell fate resulting from developmental 
xenoestrogen exposure, with a focus on the basal-type epithelial cells. We show that neonatal 
exposure to two different reference xenoestrogens induces a distinct population of aberrant 
basal cells within endometrial glands. In addition, we also identify a population of epithelial cells 
that co-express basal and luminal cell markers that we call chimeric epithelial cells. Both of 
these xenoestrogen-induced abnormal endometrial cell populations persist and increase in 
number with age and ultimately develop into neoplastic glands with either distinctive basal and 
luminal cell layers or a single layer of abnormally differentiated epithelial cells. Thus, we identify 
three populations of neoplastic cells and propose that an abnormal subset of cells with both K14 
and K18 labeling (chimeric epithelial cells) serve as progenitor cells for endometrial 
carcinogenesis. These findings support the idea that cancer risk later in life can be influenced by 
abnormal cellular differentiation patterns established during early development. 
 
Materials and Methods 
Animals and exposure groups  
All studies were performed in accordance with the recommendations in the National 
Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals, and all procedures 
involving animals were conducted according to an approved Institutional Animal Care and Use 
Committee (IACUC) protocol of the National Institute of Environmental Health Sciences 
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(NIEHS)/NIH. As described in Chapter 2, female pups were given daily subcutaneous (SC) 
injections of 1 mg/kg of DES or 50 mg/kg GEN in corn oil during postnatal days 1-5 (Newbold et 
al., 1990; Newbold et al., 2001; Suen et al., 2016). Reproductive tracts were collected at 3 or 18 
months of age. To evaluate the morphologic and molecular profile of tumor lesions, we 
evaluated a subset of mice at 18 months of age, including 9 of 30 randomly selected CON mice 
and all GEN (n=10) and DES (n=12) mice with carcinomas as determined in Chapter 2. To 
evaluate the morphologic and molecular profile of uteri prior to cancer development we 
evaluated a similar number of CON, GEN, and DES at 3 months of age (n=5-10). Additional 
mice are being evaluated to reach 10 animals per exposure group at 3 months of age. 
Histopathologic analysis 
Tissue collection and processing was performed as described previously in Chapter 2. 
Histopathologic diagnoses were based on standard criteria and nomenclature for neoplastic and 
non-neoplastic lesions (Yoshida et al., 1999; Dixon et al., 2014). All pathology data, tabulations, 
and observations were recorded by a certified veterinary pathologist. 
Immunohistochemistry and immunohistochemical analysis 
The immunohistochemical (IHC) profile of uteri from CON and GEN- or DES-exposed 
mice at 3 or 18 months of age was evaluated using standard IHC protocols per the NIEHS IHC 
core laboratory (Painter et al., 2010). Mouse uteri were evaluated for the following markers: 
Sine oculis-related homeobox 1 homolog (SIX1) as a developmental differentiation factor and 
putative cancer progenitor cell marker; Tumor protein 63 (P63) and Keratin 14 (K14) as markers 
of basal cell differentiation; Keratin 18 (K18) as a marker of luminal cell differentiation; and 
Proliferation-related Ki67 antigen (Ki67) as a cell proliferation marker. Tissue preparation for 
IHC staining was performed as described previously. Specific preparations for blocking of non-
specific binding, and primary, secondary, and negative control staining are listed in Table 3-1. 
Non-specific sites were blocked using 10% animal serum (Jackson ImmunoResearch, West 
Grove, PA) for 20 min at room temperature, followed by the avidin/biotin blocking kit (Vector 
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Laboratories, Burlingame, CA). The sections were then incubated with the appropriate 
commercially available primary antibody or negative control for 1 hr at room temperature, 
followed by incubation with appropriate secondary antibody for 30 min at room temperature. The 
sections were then incubated with a R.T.U. Vectastain Kit (Vector Laboratories, Burlingame, 
CA; SIX1, P63, K14, K18) for 30 min at room temperature and visualized using 3,3’-
diaminobenzidine (DAB) chromogen as described previously. Sections were counterstained with 
hematoxylin, dehydrated through graded ethanol, cleared in xylene, and coverslipped. 
Appropriate positive control tissues, including skin and intestine, were stained with each 
experiment. Other reproductive tract tissues present on each slide were also used as internal 
positive controls for specific markers (e.g., stratified squamous vaginal epithelium for K14 and 
P63). 
Overall IHC labeling was evaluated by light microscopy by a certified veterinary 
pathologist and assigned a qualitative labeling score from 0 to 4 (0, absent; 1, minimal; 2, mild; 
3, moderate; 4, severe) based on staining intensity and the estimated percentage of labeled 
cells within a section. Lesion-specific labeling was confirmed by comparison with corresponding 
adjacent H&E-stained sections. 
Statistical Analysis  
Statistical analyses were performed as described in Chapter 2 using GraphPad Prism, 
version 7.0. Data were analyzed using one-tailed Fisher exact test and appropriate post hoc 
tests for multiple comparisons. Tests used and statistical significance are indicated in the figure 
legends.  
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Results 
Normal adult female reproductive tract morphology 
In all exposure groups, the vaginal and cervical epithelium was composed of stratified 
squamous epithelial cells that varied based on estrous cycle stage (Yoshida et al., 1999; Dixon 
et al., 2014) (Fig. 3-1A). At or near the normal squamocolumnar junction (SCJ), a single layer of 
cuboidal basal cells was often present subjacent to the glandular or central luminal columnar 
epithelium indicating the transition from stratified squamous to simple columnar epithelium. 
These normally occurring basal cells were present in the transition zone of all CON and GEN- or 
DES-exposed mouse reproductive tracts (Fig. 3-1B). 
In CON, GEN, and DES groups, both the central uterine lumen and morphologically 
normal endometrial glands were lined by a single layer of cuboidal to columnar glandular 
epithelium (Fig. 3-1C, D). In contrast to other glands such as mammary and prostate, normal 
endometrial glands do not have a peripheral layer of myoepithelial or basal-type cells. In CON 
mice, the surrounding endometrial stroma was clearly demarcated from the myometrium and 
contrasted starkly with GEN and DES-exposed mice which lacked a clear distinction between 
the stroma and surrounding myometrium (Fig. 3-1E, F). Physiologic variations in endometrial 
morphology (e.g., mitotic and apoptotic epithelial cells, stromal edema) were evident based on 
estrous cycle stage and consistent with previously described changes (Dixon et al., 2014).  
Uterine abnormalities resulting from GEN or DES exposure 
As noted in Chapter 2, neonatal exposure to GEN or DES resulted in a spectrum of 
uterine abnormalities at 6, 12, and 18 months of age, all of which are classical features of 
neonatal estrogen exposure (Newbold et al., 1990; Newbold et al., 2001). By 18 months of age, 
significant, exposure-related uterine changes included cystic change, adenomyosis, basal cell 
and squamous metaplasia, atypical hyperplasia, and carcinoma, while few abnormalities were 
observed at 3 months of age (Table 2-1, Table 3-2). The primary difference between CON and 
GEN- or DES-exposed mice at the 3-month time point was increased incidence of basal cell 
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metaplasia/hyperplasia. Morphologic features of GEN- or DES-induced lesions at both 3 and 18 
months of age are described below. It is important to note that no qualitative differences were 
observed between GEN and DES-induced lesions and representative images are indicative of 
lesions from both exposure groups.  
By 18 months of age, uterine changes included the following: cystic change, 
adenomyosis, basal cell and squamous metaplasia, atypical hyperplasia, and carcinoma (Figs. 
3-2, 3-3). Cystic change was defined by the presence of multiple irregularly dilated endometrial 
glands that were at least 100 µm in diameter scattered along one or both uterine horns and 
distinct from central uterine lumen (Fig. 3-2A). Note that cystic change was used in place of 
cystic endometrial hyperplasia (CEH), as described in previous reports (Newbold et al., 1990), 
because a clear increase in cell number, gland number, or other proliferative changes beyond 
physiological estrous cycle-related variations could not be reliably identified as features of these 
lesions. Additionally, the diagnosis of cystic change did not include occasional cysts located at 
the cervical SCJ, which were observed in CON, GEN- and DES-exposed mice.  
Adenomyosis was defined by the presence of nonneoplastic endometrial glands with or 
without associated stroma in the myometrium or along the serosal surface (Fig. 3-2B). These 
glands were well-differentiated and lacked features of atypia or tissue invasion distinguishing 
them from atypical hyperplasia and carcinoma.  
Squamous metaplasia was defined by a maturation lineage of stratified squamous 
epithelial cells extending from the basement membrane to the lumen in place of the glandular 
epithelium (Fig. 3-2C, D). This change was distinguished from basal cell metaplasia by multiple 
layers of squamoid cells progressing to fully differentiated keratinocytes and, in some cases, 
keratinization (Fig. 3-2C). 
Basal cell metaplasia was defined by the presence of a distinct subluminal layer of 
basal-type epithelial cells adjacent to columnar glandular cells that typically line the central 
lumen and endometrial glands (Fig. 3-2E). Basal cells were often cuboidal with round to oval 
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nuclei and scant cytoplasm (Fig. 3-2F). The bilaminar appearance of basal cell metaplasia was 
often accompanied by rudimentary or multilocular luminal morphology, giving some glands an 
immature appearance (Fig. 3-2G). As described in Chapter 2, some degree of basal-type 
differentiation (beyond the junction of the cervix and uterine body) was observed in almost all 
mice exposed neonatally to DES or GEN but rarely in CON mice. Metaplasia was most often 
observed in glands of the uterine body but were also found variably along the length of the 
uterine horns.  
Basal cell metaplasia was one of the few uterine changes observed in GEN- and DES-
exposed mice at 3 months of age. At 3 months of age, small pockets of basal-type epithelial 
cells were scattered along the periphery of the primary endometrial lumen and endometrial 
glands in GEN or DES-exposed mice but not CON mice (Fig. 3-2H). IHC labeling aided in basal 
cell identification as small foci were difficult to locate with H&E analysis alone. These foci 
increased in number and size by 18 months of age and often progressed to fully encircle glands. 
Atypical hyperplasia was defined by increased numbers and layers of epithelial cells in 
endometrial glands with cytological and/or architectural atypia (Fig. 3-3A). Features of atypical 
glands included irregular growth patterns (e.g. cribriform architecture); aberrant cellular 
differentiation, including mixed glandular, basal, squamous, and mucous cells; small or irregular 
glandular lumens; and excessive crowding of ("back-to-back") glands. Cellular features included 
loss of polarity and increased anisokaryosis and anisocytosis (Fig. 3-3B). Atypical features were 
distinct from physiological changes observed as part of the normal estrous cycle.  
Endometrial carcinomas were characterized by the presence of atypical glands with 
evidence of local invasion into the surrounding stroma or myometrium (Fig. 3-3C). Vascular 
invasion was noted in rare cases (Fig. 3-3D). Carcinomas typically occurred on a background of 
atypical hyperplasia. Secondary features included desmoplasia, inflammation, and mucin and 
cell debris within neoplastic glands. The most common location of carcinomas was the uterine 
body near the bifurcation of each uterine horn (Fig. 3-3E). 
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Carcinomas showed several different morphologic variations. All carcinoma lesions had 
some degree of lumen formation, consistent with glandular differentiation and classification as 
adenocarcinomas (ADCs). However, none of the GEN- or DES-induced carcinomas had a 
characteristic gland-only phenotype consisting of basophilic glandular epithelial cells. All tumors 
showed some degree of basal-type differentiation. The most common pattern consisted of small 
glandular structures with round lumens, 1-2 layers of cells, and large “fried-egg” macrophages in 
the lumens (Fig. 3-3F). These lesions were highly infiltrative, and neoplastic cells along margins 
were often difficult to distinguish from adjacent stromal cells (Fig. 3-3F). Other neoplastic glands 
had clear evidence of squamous differentiation, as indicated by one or more layers of flattened 
epithelium with or without keratinization, basal cell and/or mucinous differentiation (Fig. 3-3G, 
H). Together these data indicate specific differentiation patterns and/or cell lineages that arise  
from neonatal xenoestrogen exposure. However, histopathologic analysis using only H&E 
images limits identification of cell type to morphology and architecture and indicates a need for 
molecular characterization using IHC labeling. 
IHC profile of normal adult female reproductive tract morphology  in CON and GEN-or DES-
exposed mice 
Region-specific labeling for SIX1, P63, K14, and K18 are listed in Table 3-3. As 
expected, the vaginal and cervical epithelium exhibited basal and squamous cell markers and 
lacked luminal/glandular cell markers. Regardless of age, all CON and GEN-or DES-exposed 
mice showed strong nuclear P63 and SIX1 labeling of basal and suprabasal layers within the 
stratified squamous epithelium (Fig. 3-4A, B). P63 labeling was generally higher intensity 
compared to SIX1 labeling in vaginal and cervical epithelium (Table 3-3). P63 labeling 
decreased in both the number of positively labeled cells and stain intensity in more superficial 
layers of squamous cells and was absent in stratum corneum (Fig. 3-4A). SIX1 labeling 
extended into the stratum corneum but labeling became weaker with squamous cell maturation 
(Fig. 3-4B). In animals in proestrus, SIX1 was also observed within the mucified cell layer (data 
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not shown). Strong cytoplasmic K14 labeling was present in all layers of the squamous 
epithelium (Fig. 3-4C). In all exposure and age groups, the vaginal and cervical squamous 
epithelium lacked K18 labeling (Figure. 3-4D; above dashed line). Additionally, at both 3 and 18 
months of age, some GEN- or DES-exposed mice had foci of vaginal adenosis which showed 
strong K18 labeling (Figure. 3-4D). Basal cells underlying the glandular epithelium at or near the 
SCJ also showed labeling for P63, SIX1, and K14 (Fig. 3-5A, B, C). K18 labeling was absent in 
SCJ-associated basal cells but present in adjacent luminal/glandular cells (Fig 3-5D).  
In all exposure and age groups, luminal/glandular epithelial cells within the primary 
uterine lumen and morphologically normal endometrial glands showed strong K18 labeling (Fig. 
3-6A). K18 labeling was predominantly membranous, to a lesser extent cytoplasmic, and most 
prominent along the apical cell surface (Fig. 3-6B). Normal glands lacked P63, SIX1, and K14 
labeling (Figs. 3-6C-F).  
IHC profile of GEN- or DES-exposure induced uterine abnormalities 
At 3 months of age, GEN- and DES-exposed mice had foci of basal cells within the 
uterus that were not associated with the SCJ. These uterine basal cells exhibited SIX1, P63, 
and K14 labeling and lacked K18, consistent with the previously described basal cell labeling 
profile (Fig. 3-7A, B; SIX1 and P63 not shown). GEN- and DES-exposed mice at both 3 and 18 
months of age also had a small percentage of immature “unfolding” glands that showed K14 
and SIX1 labeling within a single luminal cell layer that lacked clear evidence of basal cell 
differentiation (Fig. 3-7A, SIX1 not shown). These glands were often located along the deep 
margin of the endometrial epithelium. Glands with these abnormal K14 and SIX1-labeled 
luminal cells also appeared to have the expected K18 labeling based on observations from 
sequential serial sections but were negative for P63 (Fig. 3-7B, P63 not shown). We will refer to 
these cells as chimeric epithelial cells because they exhibit both basal and luminal markers, 
indicating a mixed molecular phenotype.  
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At 18 months of age, labeling of GEN- or DES-induced nonneoplastic lesions was often 
consistent with cellular morphology. Morphologically normal luminal and glandular epithelial 
cells present in areas of cystic change and adenomyosis showed the same labeling profile as 
morphologically normal glands described above (SIX1-/P63-/K14-/K18+; data not shown). Foci 
of squamous metaplasia had labeling patterns similar to normal vaginal and cervical epithelium 
(SIX1+/P63+/K14+/K18-; data not shown). Endometrial glands with basal cell metaplasia 
uniformly showed strong P63 and K14 labeling within basal cells (Fig. 3-7C, D). K18 labeling 
was observed specifically within the luminal cell layer of endometrial glands with basal cell 
metaplasia and was either absent or equivocal in the basal layer (Fig. 3-7E). The labeling 
patterns for P63, K14, and K18 indicated that morphologically-apparent basal cell metaplasia 
was comprised of well-differentiated and distinct cell compartments resembling differentiation 
patterns observed in the SCJ. However, SIX1 labeling in endometrial glands with basal 
metaplasia did not follow the labeling pattern observed in the SCJ. Instead, SIX1 labeling was 
often found in both basal cell and luminal cell compartments of metaplastic glands (Fig 3-7F). 
Furthermore, in glands with basal cell metaplasia, SIX1 was generally present only in luminal 
cells that had subjacent SIX1-labeled basal cells (Fig. 3-7G).  
Atypical hyperplastic lesions and carcinomas were comprised of a combination of the 
abnormally differentiated endometrial cell types described above. These included glands with 
bilaminar (basal and luminal) morphology, basal/squamous cell only morphology, and luminal 
cell only morphology. Bilaminar neoplastic glands showed strong expression of P63 and K14 in 
basal-type cells and K18 labeling in luminal cells, whereas SIX1 was found in both luminal and 
basal layers (Fig. 3-8; Fig. 3-9A-D). As such, K18 labeling provided a “mirror image” for K14 and 
P63 labeling and highlighted the two-compartment phenotype of some of these tumors with 
SIX1 appearing in both compartments (Fig. 3-9A-D). 
In addition, some atypical and neoplastic lesions were comprised of a single layer of 
luminal cells that lacked clear basal differentiation but had K14 labeling similar to the chimeric 
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epithelial cells observed in the immature “unfolding” glands in exposed mice at 3 months of age 
(Fig. 3-8C; Fig. 3-9B). K18 labeling was variable within lesions (Fig. 3-8D; Fig. 3-9C, F) and, 
when present, often co-expressed with SIX1 and K14 indicating a mixed luminal and basal 
molecular phenotype (Fig. 3-9B, C, E, F). Thus, GEN- and DES-induced carcinomas were 
comprised of three distinct cell populations: luminal/glandular cells (SIX1+/P63-/K14-/K18+), 
basal cells (SIX1+/P63+/K14+/K18-), and chimeric epithelial cells (SIX1+/P63-/K14+/K18+).  
Ki67 labeling within normal and abnormal endometrial epithelium 
The proliferation marker Ki67 was expressed sporadically in the glandular and luminal 
endometrial epithelium of all CON mice (Fig. 3-10A). Positively labeled cells varied considerably 
based on estrous cycle stage. Ki67 labeling within nonneoplastic basal cells in regions of basal 
cell or squamous metaplasia indicated a low proliferation rate (estimated at <2%) compared 
with morphologically normal endometrial glands in the same uterus and adjacent luminal cells in 
the same gland (Fig. 3-10B, C). Neoplastic glands comprised of luminal, basal, and/or chimeric 
epithelial cells had increased Ki67 labeling compared to nonneoplastic glands containing these 
cell types. However, the percentage of Ki67-labeled cells in neoplastic lesions was still 
remarkably low (estimated at <5%) given the undifferentiated appearance and invasive 
morphology (Fig. 3-10D).   
 
Discussion 
Developmental exposure to environmental estrogens is an established risk factor for 
cancer of the female reproductive tract. This effect is associated with disruption of normal 
cellular differentiation during critical stages of morphogenesis and reprogramming of normal 
physiologic responses. Here we showed that neonatal xenoestrogen exposure resulted in high 
numbers of basal-type cells along the perimeter of uterine glands. These cells were not present 
in control uteri beyond the junction of the cervix and uterine body. Aberrant basal-type cells 
showed positive nuclear expression of P63 and SIX1, and strong cytoplasmic staining for K14, 
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indicating widespread metaplasia of uterine glands in GEN- and DES-exposed mice. All 
endometrial carcinomas and associated hyperplastic lesions had both basal and glandular 
components. This “double phenotype” was confirmed by labeling for P63 and K14 in basal-type 
cells and K18 in luminal cells. The oncofetal protein SIX1 was present in basal and luminal cell 
compartments of bilaminar glands as well as the chimeric epithelial cells present in lesions with 
only a single luminal cell layer. Thus, we identified three specific populations of neoplastic cells. 
Two of the cell populations appear more differentiated based on either basal or luminal cell 
morphology and expression of specific basal (P63+/K14+) or luminal (K18+) markers. The third 
population was mixed, appearing morphologically similar to a neoplastic gland with only luminal 
cells (i.e. lacking clear evidence of basal cells) but expressing both luminal and basal markers 
(SIX1+/K14+/K18+).   
The delay in disease development long after the time of exposure suggests that 
neonatal xenoestrogen exposure acts as an initiator to activate processes and pathways that 
ultimately result in the transformation of a subset of uterine epithelial cells (Leavitt et al., 1981). 
As described previously, initiation of this cell population is probably not a result of xenoestrogen-
induced mutagenesis or DNA damage, but is instead most likely due to transient and/or 
permanent alterations in the epigenome. These alterations lead to a series of events that result 
in the establishment of an abnormal population of susceptible cells that are promoted by either 
endogenous estrogens beginning at puberty or exogenous estrogen administration (Leavitt et 
al., 1981; Ostrander et al., 1985; Newbold et al., 1990). Previously, we identified a population of 
SIX1-positive basal-type cells that first appear at the time of exposure, progress with disease 
development, and are a prominent feature of all neoplastic lesions. With additional IHC labeling 
described here, we identified that this cell type expresses the established basal cell markers 
P63 and K14 indicating both morphologic and molecular basal cell differentiation similar to that 
in cells found in the vaginal and cervical epithelium, and these cells were often distinct from 
adjacent K18-labeled luminal epithelial cells (Kurita et al., 2001; Kurita et al., 2004). We do not 
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know at this point whether or not the more differentiated basal cells that we initially observed at 
3 months of age, became widespread by 18 months of age, and were present in all hyperplastic 
and neoplastic lesions, actually progress to malignancy. 
The possibility that these differentiated basal cells (SIX1+/P63+/K14+/K18-) may not act 
as a cancer progenitor cell population helps reconcile several other observations: 1) Bilaminar 
endometrial glands in GEN-and DES-exposed mice have essentially the same morphology and 
IHC profile as the normal bilaminar epithelial cells of the SCJ transition region in the cervix of 
control mice, which do not progress to cancer; 2) Other mouse strains, most notably FVB, have 
background foci of mature basal cell metaplasia in the uterine body and horns, but these foci do 
not progress to cancer in control mice; 3) Genetic manipulation and/or disruption of several 
uterine epithelial regulatory pathways result in uterine basal cells that do not progress to cancer 
(Kurita, 2011); and 4) Other glands such as those in the mammary gland normally have basal 
cells surrounding luminal/glandular cells that do not usually progress to cancer. Therefore, it is 
possible that xenoestrogen-induced differentiated basal and luminal cell populations that form 
bilaminar metaplastic lesions serve as conspicuous markers of altered differentiation but that 
cancer development does not simply depend on having these metaplastic basal cells. These 
observations highlight the potential role of the chimeric epithelial cells (SIX1+/P63-/K14+/K18+) 
present in the endometrial glands of GEN- and DES-exposed mice. These chimeric epithelial 
cells were observed starting at 3 months of age prior to appearance of atypical hyperplasia or 
neoplastic lesions and were far less numerous that the more differentiated basal cells 
(SIX1+/P63+/K14+/K18-).  
Therefore, we propose that the smaller population of morphologically ambiguous 
chimeric epithelial cells that expressed both luminal and basal cell markers (SIX1+/K14+/K18+) 
serve as a cancer progenitor cell population. These cells were often present in the vicinity of 
metaplastic glands but were less numerous and had less intense K14 staining that was more 
membranous and speckled compared to prominent labeling in more mature basal cells. 
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Xenoestrogen exposure that occurs early in female reproductive tract epithelial differentiation 
may cause a subset of these chimeric epithelial cells to remain fixed in a bipotential 
differentiation state. The bipotentiality of these cells is further supported by the uniform lack of 
P63 labeling, which appears to be specific to “mature” basal cells. As such, these chimeric 
epithelial cells may be the susceptible cells that were initiated by neonatal xenoestrogen 
exposure. The mitogenic effects of later estrogen exposure may then promote transformation 
(and differentiation) of this unique cell population into endometrial carcinomas that have a 
combination of luminal, basal, and chimeric cell phenotypes. 
These ideas align with prior evidence variably described as the “stem cell theory of 
cancer”. This theory proposes that tumors are comprised of a large number of well-differentiated 
proliferative cells that make up a majority of the tumor and a small number of low-proliferating, 
poorly differentiated refractory cells with stem cell-like properties that initially produced the 
tumor and/or continue to sustain it (Nguyen et al., 2012). For example, evidence from the breast 
cancer literature indicates that undifferentiated terminal ductal cells influence later-life cancer 
risk and that differentiation of these cells induced by pregnancy acts as a protective mechanism 
(Dontu et al., 2004; Russo et al., 2005). Furthermore, we observed that basal cells, chimeric 
epithelial cells, and neoplastic lesions all had low Ki67 labeling. Slow growing basal 
myoepithelial cells have been described as a population of mammary stem cells that act as an 
adult progenitor population for both luminal and additional basal cells (Rios et al., 2014; 
Visvader and Stingl, 2014).  
Although we observed the chimeric endometrial epithelial cells in early adulthood (3 
months of age) in neonatally exposed mice, we have not looked for these cells using K14 and 
K18 labeling on PND5 when SIX1 labeled cells are first observed as described in Chapter 2. It is 
possible that these chimeric epithelial cells arise at the time of exposure and are maintained 
throughout life. Furthermore, it is unclear at this time if the chimeric epithelial cell population 
serves as a precursor to differentiated glands with basal cell metaplasia or if they are a result of 
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de-differentiation of basal cell populations. To understand the establishment and progression of 
chimeric epithelial cell following exposure, additional staining needs to be done at PND5, 
prepubertally, and postpubertally using multicolor fluorescence imaging to confirm co-
expression (SIX1, K14, and K18) and to create a timeline for this cell population. 
Regardless of the cellular differentiation pattern, SIX1 appears to be an excellent marker 
of abnormal differentiation following neonatal GEN or DES exposure. These findings support the 
idea that SIX1 may play a role in carcinogenesis in this mouse model of neonatal xenoestrogen 
exposure. The role of SIX1 as a differentiating factor has been described in multiple tissue types 
both during development and in adult animals (Christensen et al., 2008; Swetha et al., 2011; Le 
Grand et al., 2012; Yajima et al., 2014). For example, following muscle injury, SIX1 drives stem 
cell commitment and differentiation and regulates stem cell renewal (Le Grand et al., 2012). 
These data suggest that SIX1 in uterine basal cell populations is functioning to maintain a 
progenitor-like cell population, as well as drive differentiation.  
A growing body of evidence supports the idea that chemical exposure during 
development can increase cancer risk later in life. DES and other estrogens provide an 
important case study for this concept. However, there remains a critical need for better 
biomarkers and mechanistic information linking early exposure to estrogenic chemicals to 
reproductive outcomes. Here we examined differentiation patterns over time for endometrial 
epithelial cells following neonatal GEN- and DES-exposure and identified distinct cell 
populations associated with endometrial cancer development. These results inform the 
relationship between early developmental exposure to estrogenic chemicals, persistent 
biological changes, and disease pathogenesis. Future studies are needed to characterize 
molecular drivers of these differentiation patterns, including SIX1 and other biomarkers of 
endometrial cancer development. Furthermore, genetic manipulation of SIX1 is necessary to 
determine if it plays a role in endometrial carcinogenesis and/or establishment of the chimeric 
epithelial cell population. 
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Table 3-1 Antibodies used for immunohistochemistry 
Antibody Provider Cat # Lot # Concentration Serum 
Primary 
Anti-SIX1 Sigma-Aldrich St. Louis, MO HPA001893 C75776 0.2 ug/mL Donkey  
Anti-P63 Santa Cruz Biotechnology Santa Cruz, CA sc-8343 C2012 0.4 ug/mL Goat 
Anti-K14 Covance Princeton, NJ PRB-155P D13EF01483 0.8 ug/mL Donkey 
Anti-K18 Santa Cruz Biotechnology Santa Cruz, CA sc-51582 H2714 8 ug/mL Horse 
Anti-Ki67 Biocare Medical Concord, CA CRM325C 020314 1.1 ug/mL Rodent Block M 
Negative Control 
Rabbit IgG  
(P63, SIX1) Calbiochem Billerica, MA NIO1 D00168753 Equivalent  Dilution   
Rabbit IgG (K14) EMD Millipore Billerica, MA NIO1 D00168753 Equivalent  Dilution   
Mouse IgG1 (K18) BD Biosciences San Jose, CA 557273 4241584 Equivalent  Dilution   
Secondary 
Donkey anti-rabbit 
(SIX1, K14) Jackson Immunoresearch  West Grove, PA 711-065-152 124459 2.2 ug/mL  
Goat anti-rabbit 
(P63) Vector Laboratories Burlingame, CA BA-1000 ZA0924 3 ug/mL  
Horse anti-mouse 
(K18) 
Vector Laboratories 
Burlingame, CA BA-2001 Z0421 0.5 ug/mL  
Rabbit on rodent 
HRP (Ki67) Biocare Medical Concord, CA NA NA NA  
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Table 3-2 Incidence of reproductive tract abnormalities in GEN- 
or DES-exposed mice at 3 months of age 
Location Pathology  CON GEN DES 
Vagina Adenosis  0/13 (0%) 0/5 (0%)  3/8 (38%) 
Uterus Cystic change  0/13 (0%) 0/5 (0%)  0/8 (0%) 
 Adenomyosis  0/13 (0%) 0/5 (0%)  0/8 (0%) 
 Basal cell metaplasia  1/13 (8%) 4/5 (80%)  8/8* (100%) 
 Squamous metaplasia1  0/13 (0%) 1/5 (20%)  0/8 (0%) 
 Atypical hyperplasia  0/13 (0%) 0/5 (0%) 0/8 (0%) 
 Carcinoma  0/13 (0%) 0/5 (0%)  0/8 (0%) 
 Sarcoma  0/13 (0%) 0/5 (0%)  0/8 (0%) 
Abbreviations: CON, control; GEN, genistein; DES, diethylstilbestrol; 
NA, not applicable 
*Significant using one-tailed Fisher exact test P<0.05 compared to 
corresponding age-matched CON mice 
n=5-13 mice per exposure and age group as indicated in the table 
1Stratified squamous epithelial cells replacing glandular epithelium; 
distinct from a single layer of basal cells 
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 Table 3-3A Expression of immunohistochemical markers in the female reproductive tract of mice 
exposed neonatally to GEN or DES 
   Age (months) 
   3  18 (cancer) 
IHC Site  CON GEN DES   CON GEN DES 
SIX1 Vaginal epithelium  13/13 (100%) 5/5 (100%) 8/8 (100%)  9/9 (100%) 10/10 (100%) 12/12 (100%) 
 Labeling index1  2.2 2.0 1.9   1.8 1.4 1.6 
 Nonneoplastic 
endometrial epithelium  1/13 (8%) 5/5* (100%) 7/8* (88%)   0/9 (0%) 10/10* (100%) 12/12* (100%) 
 Labeling index1  0.1 1.0 0.9  0.0 2.2 2.6 
 Neoplastic 
endometrial epithelium  NA NA NA  NA 10/10 (100%) 12/12 (100%) 
 Labeling index1  NA NA NA   NA 2.0 2.5 
P63 Vaginal epithelium  13/13 (100%) 5/5 (100%) 8/8 (100%)  9/9 (100%) 10/10 (100%) 12/12 (100%) 
 Labeling index1  2.7 3.0 2.0  2.6 2.7 2.8 
 Nonneoplastic 
endometrial epithelium  1/13 (8%) 4/5* (80%) 7/8* (88%)  4/9 (44%) 10/10* (100%) 12/12* (100%) 
 Labeling index1  0.1 0.8 0.9  0.4 2.0 2.5 
 Neoplastic 
endometrial epithelium  NA NA NA  NA 10/10 (100%) 12/12 (100%) 
 Labeling index1  NA NA NA  NA 2.1 1.9 
Abbreviations: CON, control; GEN, genistein; DES, diethylstilbestrol; NA, not applicable. 
n=5-13 mice per exposure and age group as indicated in table 
*Significant using one-tailed Fisher exact test P<0.05 compared with corresponding age-matched control mice. 
1Average qualitative labeling score from 0 to 4 for IHC labeling within that group 
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 Table 3-3B Expression of immunohistochemical markers in the female reproductive tract of mice 
exposed neonatally to GEN or DES 
   Age (months) 
   3  18 (cancer) 
IHC Site  CON GEN DES   CON GEN DES 
K14 Vaginal epithelium  13/13 (100%) 5/5 (100%) 8/8 (100%)  9/9 (100%) 10/10 (100%) 12/12 (100%) 
 Labeling index1  4.0 4.0 4.0  4.0 4.0 4.0 
 Nonneoplastic 
endometrial epithelium  1/13 (8%) 5/5* (100%) 8/8* (100%)  1/5 (20%) 10/10 (100%) 12/12* (100%) 
 Labeling index1  0.1 1.0 1.0  0.2 2.5 2.7 
 Neoplastic 
endometrial epithelium  NA NA NA  NA 10/10 (100%) 12/12 (100%) 
 Labeling index1  NA NA NA  NA 3.5 3.2 
K18 Vaginal epithelium  0/12 (0%) 1/5 (20%) 1/8 (13%)  0/5 (0%) 3/6 (50%) 5/12 (42%) 
 Labeling index1  1.0 0.2 0.1  0.0 0.5 0.4 
 Nonneoplastic 
endometrial epithelium  12/12 (100%) 5/5 (100%) 8/8 (100%)  4/9 (44%) 6/6 (100%) 12/12 (100%) 
 Labeling index1  3.8 4.0 4.0  0.4 4.0 2.7 
 Neoplastic 
endometrial epithelium  NA NA NA  NA 6/6 (100%) 12/12 (100%) 
 Labeling index1  NA NA NA  NA 3.2 3.2 
Abbreviations: CON, control; GEN, genistein; DES, diethylstilbestrol; NA, not applicable 
n=5-13 mice per exposure and age group as indicated in table 
*Significant using one-tailed Fisher exact test P<0.05 compared with corresponding age-matched control mice 
1Average qualitative labeling score from 0 to 4 for IHC labeling within that group 
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Figure 3-1 Representative images of normal female reproductive tract morphology in 
CON and GEN- or DES-exposed mice. A. Vaginal epithelium; 20x. B. Transition zone with 
squamocolumnar junction. Arrows indicate subjacent basal cells; 20x. C. Normal uterine 
epithelium from CON mouse; 20x. D. Morphologically normal uterine epithelium from DES-
exposed mouse; 20x. E. Distinct stromal and myometrial compartments in CON mouse; 20x. F. 
Less defined stromal and myometrial compartments in DES-exposed mouse; 20x. Slides for all 
images were stained with hematoxylin and eosin (H&E) (A-F).  
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Figure 3-2 Representative images of nonneoplastic uterine changes in GEN- and DES-
exposed mice. Figure legend continues on the following page.  
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Figure 3-2 Representative images of nonneoplastic uterine changes in GEN- and DES-
exposed mice. A. Cystic change; 4x. B. Adenomyosis. Dashed line roughly divides 
myometrium (top) and stroma (bottom). Arrowheads indicate nonneoplastic endometrial glands 
within the myometrium; 10x. C. Squamous metaplasia. Arrow indicates metaplastic gland with 
clear squamous maturation lineage; 20x. D. Squamous metaplasia without complete maturation 
lineage; 40x. E. Basal cell metaplasia with distinct subluminal layer of cuboidal cells surrounding 
gland; 40x. F. High magnification of basal cells; 60x. G. Basal cell metaplasia with multilocular 
appearance; 40x. H. Small foci of basal cells in a 3-month old mouse (arrows); 20x. Slides for all 
images were stained with H&E (A-H). 
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Figure 3-3 Representative images of proliferative and neoplastic lesions in GEN- and 
DES-exposed mice at 18 months of age. Figure legend continues on the following page. 
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Figure 3-3 Representative images of proliferative and neoplastic lesions in GEN- and 
DES-exposed mice. A. Atypical hyperplasia of uterine glands; 20x. B. Atypical hyperplasia with 
mitoses, anisokaryosis/anisocytosis; 40x. C. Endometrial carcinoma; 4x. D. Endometrial 
carcinoma with vascular invasion (arrow); 40x. E. Arrows indicate carcinoma lesions in the 
uterine body and bifurcation of horns; 1x. F. Infiltrative neoplastic cells that are difficult to 
distinguish from stromal cells and fried egg macrophages in the gland lumen; 40x. G. 
Carcinoma with squamous differentiation (arrows); 20x. H. Carcinoma with basal and mucous 
cell differentiation; 60x. Slides for all images were stained with H&E (A-H). 
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Figure 3-4 IHC profile of the vaginal epithelium in CON and GEN- or DES-exposed mice. 
Figure legend continues on the following page. 
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Figure 3-4 IHC profile of the vaginal epithelium in CON and GEN- or DES-exposed mice. 
P63 (A), SIX1 (B), and K14 (C) labeling in the stratified squamous epithelium; 20x. D. K18 is 
absent in the squamous epithelium (above dashed line) but present in a focus of vaginal 
adenosis in a DES-exposed mouse (arrow); 20x. 
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Figure 3-5 IHC profile of the transition zone in CON and GEN- or DES-exposed mice. P63 
(A), SIX1 (B), and K14 (C) labeling in the basal cells within the SCJ (arrows), highlighting the 
normal bilaminar morphology; 20x. D. K18 labeling within the luminal epithelial cells. Arrowhead 
indicates luminal cells and arrow indicates basal cells; 20x. 
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Figure 3-6 IHC profile of morphologically normal endometrial glands in CON and GEN- or 
DES-exposed mice. A. K18 labeling of glandular epithelium; 20x. B. Cytoplasmic and 
membranous localization of K18 labeling; 60x. Lack of uterine P63 (C), SIX1 (D), and K14 (E) 
labeling in a CON mouse; 20x. F. Lack of uterine K14 labeling in normal endometrial glands 
within a DES-exposed mouse (region with no basal cell metaplasia); 20x.  
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Figure 3-7 IHC profile of basal cell metaplasia in GEN- and DES-exposed mice. Figure 
legend continues on the following page.  
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Figure 3-7 IHC profile of basal cell metaplasia in GEN- and DES-exposed mice. A. K14 
labeling in foci of basal cells (arrows) and chimeric epithelial cells within immature, “unfolding” 
glands (arrowhead) in a GEN-exposed mouse at 2 months of age; 20x. B. Lack of K18 labeling 
in foci of basal cells within the same GEN-exposed mouse at 2 months of age as shown in A. 
Arrows indicates same foci as in A; 20x. C. P63 labeling of basal cell metaplasia in a DES-
exposed mouse at 18 months of age; 20x. D. K14 labeling of mature basal cells in metaplastic 
glands; 40x. E. K18 labeling in the luminal but not basal compartment of an endometrial gland 
with basal metaplasia; 60x. F. SIX1 labeling within luminal and basal compartments of glands 
with basal metaplasia; 40x. G. SIX1 labeling present only in luminal epithelial cells with 
subjacent SIX1 labeled basal cells; 60x. 
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Figure 3-8 IHC profile of hyperplastic and neoplastic lesions in GEN- and DES-exposed 
mice at 18 months of age. A. P63 labeling in basal but not luminal cells of uterine glands with 
atypical hyperplasia; 20x. B. SIX1 labeling in basal and luminal cells of uterine glands with 
atypical hyperplasia; 20x. C. K14 labeling in invasive, microcystic neoplastic glands. Note 
luminal layer in some neoplastic bilaminar glands that lacks K14 labeling; 20x. D. K18 labeling 
in neoplastic glands; 20x. 
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Figure 3-9 IHC profile of neoplastic glands with multiple differentiation patterns in GEN- 
and DES-exposed mice at 18 months of age. A. P63 labeling in the basal compartment of 
neoplastic glands (arrow). B. K14 labeling in the basal compartment of bilaminar neoplastic 
glands (arrow) and a neoplastic gland with a single layer of chimeric epithelial cells (asterisk). C. 
K18 labeling in the luminal compartment of bilaminar neoplastic glands (arrowhead) and a 
neoplastic gland with a single layer of chimeric epithelial cells (asterisk). Asterisks in B and C 
denote neoplastic chimeric epithelial cells with a mixed molecular phenotype in luminal cell-only 
lesions. D. SIX1 labeling within neoplastic cells of all differentiation/IHC phenotypes previously 
described. A-D show stained serial sections within the same region; 60x. E. K14 labeling 
(arrows) in neoplastic glands with chimeric epithelial cells that lack clear basal cell 
differentiation; 60x. F. Neoplastic glands that have K18 labeling (asterisk) or lack K18 labeling 
(arrow); 60x.  
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Figure 3-10 Ki67 labeling in normal endometrium, basal cell metaplasia, and neoplastic 
lesions. A. Ki67 labeling in normal uterine glands; 20x. B and C, Ki67 labeling within glands 
with basal cell metaplasia. Ki67 labeling is more prominent in the luminal cell layer; 40x. D. Ki67 
labeling within a carcinoma lesion in an DES-exposed mouse at 18 months of age; 40x. 
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CHAPTER 4 – ROLE OF THE SIX1 ONCOPROTEIN IN ENDOMETRIAL CARCINOGENESIS 
CAUSED BY NEONATAL XENOESTROGEN EXPOSURE 
 
Introduction 
It is well established that early life exposure to xenoestrogens can cause adverse 
reproductive effects, including increased risk of infertility and cancer. However, the mechanisms 
underlying these processes remain unknown. In one of the most widely used mouse models to 
study early life origins of cancer, female mice are neonatally exposed to the synthetic estrogen 
diethylstilbestrol (DES). This model has been used to show that neonatal xenoestrogen 
exposure causes characteristic uterine phenotypes likely as a result of aberrant cellular 
reprogramming and differentiation during early development. Two important features of this 
model should be highlighted: 1) DES is a potent xenoestrogen that disrupts and reprograms 
gene expression, and 2) DES exposure occurs during a critical period of uterine tissue 
patterning when cells develop characteristic gene expression patterns and are fated to specific 
morphologic and cellular differentiation pathways (e.g., gland budding and development in the 
uterus). Other types of xenoestrogens, such as genistein (GEN), have been shown to induce 
similar effects, but target pathways initiated by xenoestrogen exposure that mediate uterine 
cancer development later in life are currently unknown. 
As described in Chapter 1, SIX1 is an oncofetal protein that is essential for normal organ 
development, regulates progenitor cell maintenance and differentiation, and is associated with 
cancer development in a number of human and animal studies. SIX1 is expressed in several 
different types of human tumors, including ~25% of endometrial cancers as shown in Chapter 2. 
In Chapter 2, we also demonstrated that SIX1 becomes aberrantly expressed in the uteri of 
69 
mice exposed neonatally to DES or GEN, persists with age, and localizes to abnormal uterine 
basal cells and all neoplastic lesions. In-depth histopathological and immunohistochemical 
analysis of xenoestrogen-induced uterine changes in Chapter 3 further revealed that cells 
labeled for SIX1 have an abnormal differentiation pattern over time and are associated with 
carcinogenesis. Taken together, these data suggest that SIX1 plays a functional role in uterine 
carcinogenesis induced by early-life xenoestrogen exposure.  
Here we investigate if SIX1 is necessary or sufficient for uterine carcinogenesis using 
two different genetic mouse models. First, we tested if SIX1 is necessary for uterine 
carcinogenesis in mice exposed neonatally to DES by using a conditional knockout mouse 
model in which Six1 is deleted in the uterus. Second, we tested if SIX1 is sufficient to induce 
carcinogenesis independent of xenoestrogen exposure by using a transgenic mouse model 
where SIX1 is permanently expressed in the uterus. Together, these targeted models will inform 
the role of SIX1 in the development of xenoestrogen-induced uterine cancer.  
 
Materials and Methods 
Animals 
Care and use of study animals followed an approved institutional animal care and use 
protocol pursuant to NIEHS/NIH animal care guidelines. All genetic mouse founders were bred 
to FVB/NJ mice for five generations to obtain the lines on an FVB/NJ background. Mice 
containing loxP sites flanking Six1 (Six1f/f) mice were provided by Dr. Pascal Maire (Le Grand et 
al., 2012). The 5th generation FVB backcross heterozygous animals were inbred to generate 
Six1+/+ and Six1f/f founder lines. Mice containing a CAG-loxP-STOP-loxP-Six1-Flag cassette 
knocked into the ROSA26 locus (Six1Tg/+) were provided by Dr. Kayoshi Kawakami (Yajima et 
al., 2014). Mice containing cre-recombinase under control of the endogenous progesterone 
receptor promoter (Pgr-cre) were provided by Drs. Franco DeMayo and John Lydon (Soyal et 
al., 2005). The Pgr-cre line induces CRE expression as early as PND3 in Pgr-expressing cell 
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types including the uterine luminal epithelium, stroma, and myometrium (Dunlap et al., 2011; 
Hayashi et al., 2011). Six1f/f or Six1Tg/+ mice bred to mice expressing the Pgr-cre transgene 
produced the uterine-specific conditional Six1 knockout line (Six1d/d) or the transgenic Six1 
overexpression line (Six1Tg/+;Pgr-cre), respectively. 
Mouse pups in the uterine-specific conditional Six1 deletion study were given 
subcutaneous injections (0.02 mL) of vehicle alone (corn oil), or diethylstilbestrol (DES; 1 
mg/kg) on the day of birth (postnatal day 1 [PND1]) through PND5, consistent with the 
previously described DES exposure model. To test if conditional deletion of SIX1 prevents 
endometrial cancer development, sample sizes were calculated based on previously published 
studies showing that 45% of FVB/N mice exposed neonatally to DES develop cancer by 8 
months of age (Couse et al., 1997; Davis et al., 2012). We estimated that using 12 mice per 
exposure group and genotype would allow us to detect a 45% difference in cancer incidence 
(one-sided 0.05 level of significance with 80% power) beginning at 6 months of age.  
To test if conditional overexpression of SIX1 is sufficient for endometrial cancer 
development, sample sizes were calculated based on previously published studies showing that 
24% of C57BL/6 mice with mammary gland-specific overexpression of SIX1 develop cancer by 
18 months of age (McCoy et al., 2009). We estimated that using 26 mice per exposure group 
and genotype would allow us to detect a 25% difference in cancer incidence (one-sided 0.05 
level of significance with 80% power) in FVB/N strain by 12 months of age. Animals from 
preliminary studies are presented here; we will continue to increase our animal numbers with 
additional groups as based on the power calculation. 
Mice were euthanized by decapitation on PND5 or by CO2 asphyxiation at 6 months of 
age. On PND5, both uterine horns were collected, snap-frozen on dry ice, and stored at -80°C 
until use. At 6 months of age, 1-2 mm of the cranial portion of the right uterine horn was 
removed, snap-frozen on dry ice, and stored at -80°C until use. The remaining adult 
reproductive tract (caudal portion of the uterine horn, intact left horn with ovary, cervix, and 
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vagina) was affixed dorsal side down with pins on a square of modeling wax to maintain an 
even plane during overnight fixation in formalin. Tissues were processed using standard 
histologic procedures, sectioned longitudinally at 6 µm, and stained with hematoxylin and eosin 
(H&E) or left unstained for immunohistochemistry (IHC). 
Immunohistochemistry 
Immunohistochemical staining to detect SIX1, K14, K18, and Ki67 was performed as 
described in Chapter 3. Appropriate positive and negative control tissues were stained for all 
IHC experiments. 
Histopathological Analysis 
Three H&E sections of the reproductive tract (24 µm apart) were evaluated by a certified 
study pathologist blinded to genotype. Histopathologic diagnoses were based on standard 
criteria and nomenclature for nonneoplastic and neoplastic lesions described previously in 
Chapters 2 and 3. Evaluation was performed using light microscopy, and images were captured 
with a Lumenera Infinity 2-3C digital camera (Ottawa, Ontario). 
Immunohistochemical Analysis 
SIX1, K14, and K18 labeling in the cervical/vaginal or uterine epithelium was evaluated 
for overall abundance and assigned a qualitative labeling score from 0 to 4 (0, absent; 1, 
minimal; 2, mild; 3, moderate; 4, severe) based on staining intensity and the estimated 
percentage of labeled cells within a section. Lesion-specific localization of labeling was 
confirmed as needed by comparison across labeled serial sections and with corresponding 
adjacent H&E-stained sections. 
Image Analysis 
Whole slides were scanned at 40x magnification using the Aperio Digital Pathology Slide 
Scanner (Leica Biosystems, Buffalo Grove, IL). A single K14 or K18 labeled slide per animal 
was analyzed for marker expression using the Aperio Positive Pixel Count macro. The uterine 
horn region of interest (ROI) was defined as the area above the left horn bifurcation up to the 
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utero-tubal junction. The uterine body ROI was defined as the area above the squamocolumnar 
junction (visible stratified squamous epithelium) up to the horn bifurcation. Region-specific 
quantification of K14 or K18 expression was based on the total number of strong positive pixels 
per ROI. Image analysis was performed blinded to genotype and exposure group. 
Real time RT-PCR 
Real time RT-PCR was performed as described in Chapter 2 using Six1 primers (F: 
CTGCCGTCGTTTGGTTTTAC; R: TTGTAGAGCTCGCGGAAGTT) and normalized to 
cyclophilin A (Ppia). Transcript expression levels were calculated using the delta Ct method 
(Jefferson et al., 2011; Pfaffl, 2001). 
Immunoblots 
Immunoblotting was performed as described in Chapter 2 using nuclear protein 
extracted from whole uterine tissue.  
Statistical Analysis 
GraphPad Prism, version 7.01 (La Jolla, CA) was used to perform statistical analyses. 
Data were analyzed using 2-way ANOVA or one-tailed Fisher exact test and appropriate post 
hoc tests for multiple comparisons. Tests used and statistical significance are indicated in 
Figure Legends. Error bars show the standard error of the mean (SEM) for all graphs. 
 
Results 
Neonatal DES exposure does not induce Six1 transcript or protein expression in conditional 
Six1 knockout mice. 
SIX1 is not normally expressed in the uteri of control mice during neonatal life or in 
adulthood, suggesting it is not required for normal uterine development and function. Le Grand 
et al. (2012) previously showed that a conditional knockout mouse model with loxP sites 
inserted into the 5’ UTR of Six1 exon1 and intron 1 could be used to specifically ablate Six1 in 
muscle progenitor cells (Fig. 4-1A). To investigate if Six1 could be conditionally ablated in the 
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female reproductive tract during neonatal development without altering normal morphology or 
differentiation, Six1f/f mice were bred to Pgr-cre expressing mice to induce cre-mediated 
recombination in all uterine tissue compartments (epithelium, stroma, and myometrium). 
Consistent with previous results, control Six1+/+ and Six1d/d mice exhibited low levels of uterine 
Six1 transcript and no SIX1 protein by immunoblotting at PND5 and 6 months of age (Fig. 4-1B, 
C). There were also no SIX1 labeling by IHC in the uteri of either control group at 6 months of 
age except for a few foci of SIX1-labeled cells with equivocal staining in the uterine body of a 
single control Six1+/+ mouse. As expected, there was a lack of SIX1 labeling in the vaginal 
epithelium of control Six1d/d mice (Fig. 4-1D). SIX1 labeled mast cells and other immune cells, 
which do not express PGR, were located in the endometrium and ovary of control Six1d/d mice 
and served as an internal positive staining control. There were no morphologic differences 
observed in uteri or vagina from control Six1+/+ and Six1d/d mice and the general lack of SIX1 
expression did not interfere with staining quality or distribution for the vaginal squamous cell 
marker, K14, or the uterine glandular epithelial cell marker, K18 (data not shown). Together, 
these data indicated that the Six1 knockout model could be used to achieve selective Six1 
ablation in the female reproductive tract during neonatal development without altering normal 
morphology. 
To validate the efficiency of the model in the presence of DES exposure and over time, 
we also measured Six1 transcript levels by quantitative RT-PCR and performed immunoblotting 
on PND5 and at 6 months of age in Six1+/+ and Six1d/d mice exposed neonatally to DES (Fig. 4-
1B, C). Consistent with previous results, DES-exposed Six1+/+ mice exhibited Six1 transcript 
expression on PND5 that increased >20-fold by 6 months of age. In contrast, Six1 transcript 
expression in DES-exposed Six1d/d mice was very low, comparable to control Six1+/+ and Six1d/d 
mice at both PND5 and 6 months of age. Concordant with uterine Six1 transcript levels, SIX1 
protein was observed in DES-exposed Six1+/+ mice but not in DES-exposed Six1d/d mice except 
for a few foci of SIX1-labeled cells with equivocal staining in the vaginal epithelium of a single 
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DES-exposed Six1d/d mouse. These findings indicated that the Six1 knockout model could be 
used to prevent the aberrant uterine SIX1 expression that is typically induced by neonatal DES 
exposure.   
Conditional Six1 ablation prevents DES-induced basal cell metaplasia in the uterine horns but 
not uterine cancer. 
To investigate if conditional Six1 ablation prevents characteristic DES-induced 
phenotypes, we evaluated histopathological changes in DES-exposed Six1+/+ and Six1d/d mice. 
DES-exposed Six1+/+ mice exhibited the expected range of histopathological effects as reported 
previously in Chapter 2 and 3. Effects included adenomyosis, basal and squamous metaplasia 
of endometrial glands, atypical hyperplasia, and carcinomas often with adenosquamous 
differentiation patterns (Table 4-1). Uterine carcinoma was observed in 40% of DES-exposed 
Six1+/+ mice but not in control Six1+/+ mice (Fig. 4-2A). Along with adenosquamous morphologic 
features, all carcinomas in DES-exposed Six1+/+ exhibited basal cells with K14 labeling, luminal 
cells with K18 labeling, and chimeric epithelial cells with both K14 and K18 labeling within 
neoplastic lesions in both the uterine body and horns (Table 4-2, Fig. 4-2B and C).  
DES-exposed Six1d/d mice showed a similar general pattern of histopathological findings 
compared to DES-exposed Six1+/+ mice (Table 4-1). Uterine carcinomas were observed in 78% 
of DES-exposed Six1d/d mice but not in control Six1d/d mice (Table 4-1, Fig. 4-2A). The presence 
of basal and squamous metaplasia of endometrial glands (predominantly in the uterine body), 
atypical hyperplasia, and carcinomas in the absence of SIX1 indicates that SIX1 is not required 
for DES-induced carcinogenesis in the uterus (Table 4-2). Carcinomas within DES-exposed 
Six1d/d mice also exhibited cells that co-expressed both basal cell and luminal cell markers, 
similar to those described as chimeric epithelial cells in Chapter 3. These cells expressed both 
the luminal cell marker K18 as well as limited K14 expression, which was distinct but weaker in 
intensity compared to the dense cytoplasmic labeling typical of more differentiated basal cells 
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(Fig. 4-2C). These K14 and K18-labeled cells were found in both the uterine body and horns of 
both DES-exposed Six1+/+ and Six1d/d mice.  
There were several notable differences in histopathology between DES-exposed Six1+/+ 
and Six1d/d mice. As mentioned previously, carcinomas found in both the uterine body and horns 
of DES-exposed Six1+/+ mice had basal cell differentiation based on cell morphology and K14 
labeling. However, carcinomas with basal cell differentiation found in DES-exposed Six1d/d mice 
were limited to the uterine body. Interestingly, neoplastic lesions within the uterine horns of 
DES-exposed Six1d/d mice exclusively exhibited a single luminal cell layer comprised of K14 and 
K18-labeled chimeric epithelial cells and no morphological basal differentiation (Fig. 4-2C). 
Additionally, DES-exposed Six1d/d mice had an overall decrease in the incidence of squamous 
metaplasia and severity of basal cell metaplasia. 
To investigate the decrease in metaplasia, we quantified the total number of strong 
positive K14 or K18-labeled pixels as a measure of basal/squamous cells or luminal epithelial 
cells, respectively, in a single uterine horn from each control and DES-exposed Six1+/+ and 
Six1d/d mouse (Fig. 4-3A, B). We found that compared to control Six1+/+ and Six1d/d mice, DES-
exposed Six1+/+ mice had ~12-fold higher K14-positive pixels within the uterine horn (Fig. 4-2C). 
This increase was completely abolished in DES-exposed Six1d/d mice, indicating that SIX1 
drives differentiation and/or expansion of aberrant endometrial basal cells within the uterine 
horns. Regardless of genotype, DES exposure resulted in a characteristic decrease in 
endometrial glands as indicated by an overall decrease in K18-positive pixels (Fig. 4-3D) 
(Cooke et al., 2013). This finding indicates that the decreased basal cell metaplasia in the 
uterine horns of DES-exposed Six1d/d mice is a result of Six1 ablation and not due to a more 
general effect on endometrial gland development.  
We also quantified K14-positive pixels in the uterine body in DES-exposed Six1+/+ and 
Six1d/d mice. There was a partial (~30%), although not significant, reduction in the number of 
K14-positive pixels in the uterine body of DES-exposed Six1d/d mice as compared to DES-
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exposed Six1+/+ mice (Fig. 4-2E). These data indicate that DES-induced SIX1 expression is 
acting as a differentiation factor leading to basal cell and squamous metaplasia specifically in 
the anterior portion of the uterus (uterine horns). However, in the more posterior portion of the 
uterus (uterine body) basal cells are present in the absence of SIX1, indicating that it is not 
required for the basal cell phenotype in this location. Taken together, these data suggest that 
DES-induced SIX1 plays a role in aberrant epithelial patterning and differentiation of basal cells 
in the uterus. 
Mice expressing SIX1 transgenically do not develop endometrial cancer or basal cell metaplasia 
by 6 months of age. 
To investigate if SIX1 overexpression is sufficient to induce endometrial carcinoma 
independent of neonatal xenoestrogen exposure we used a SIX1 transgenic mouse model.  
Yajima et al. (2014) previously showed that a mouse harboring a loxP-STOP-loxP-SIX1 
cassette behind the CAG promoter could be used to induce functional SIX1 expression in 
sensory neurons. To test if transgenic SIX1 expression could be induced in all uterine 
compartments during neonatal life and maintained into adulthood, Six1Tg/+ mice were bred to 
Pgr-cre mice and collected at PND5 or 6 months of age. Transgenic SIX1 protein expression in 
the uteri of Six1Tg/+;Pgr-cre mice was confirmed by immunoblotting for both SIX1 and the Flag 
tag on PND5 and at 6 months of age (Fig. 4-4B). Immunohistochemical staining for SIX1 at 6 
months of age indicated transgenic SIX1 expression in all uterine tissue compartments (Fig. 4-
4C).  
Histopathological analysis indicated that there was normal SIX1 and K14 expression 
patterns in the vaginal and cervical epithelium in all control and Six1Tg/+;Pgr-cre mice (data not 
shown). SIX1 labeling was observed in luminal epithelial cells of glands as well as endometrial 
stromal and myometrial cells in Six1Tg/+;Pgr-cre mice but not in controls (Fig. 4-4C). However, 
SIX1 labeling within the glandular epithelium was usually weak and present in a low number of 
cells (estimated at <2% total), whereas SIX1 labeling was stronger and present in higher 
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numbers of endometrial stromal and myometrial cells (often >10% of total cells). Consistent with 
previous observations, there were limited small foci of basal cells with SIX1 and K14 labeling 
typically located near the uterine junction in both control and Six1Tg/+;Pgr-cre mice. However, 
there was no evidence of endometrial carcinomas or cytologic and/or architectural atypia in 
endometrial glands in Six1Tg/+;Pgr-cre mice. Furthermore, no other DES-like pathologies (e.g., 
adenomyosis, vaginal adenosis, basal cell or squamous metaplasia, or K14/K18-labeled 
chimeric epithelial cells) were observed. Taken together, these data revealed that SIX1 
expression alone is not sufficient to cause characteristic DES-induced uterine pathologies by 6 
months of age. 
 
Discussion 
Here we demonstrated that permanent ablation of Six1 in the uteri of mice exposed 
neonatally to DES does not prevent endometrial carcinogenesis and does not alter the 
adenosquamous-type carcinoma or appearance of basal cells in the uterine body. However, in 
the absence of SIX1, chimeric epithelial cells expressing both K14 and K18 became a 
prominent feature of atypical and neoplastic lesions in the uterine horns of DES-exposed Six1d/d 
mice. Furthermore, DES-exposed Six1d/d mice had decreased basal cell and squamous 
metaplasia within the uterine horns. Together these data indicate that SIX1 mediates 
differentiation of endometrial epithelial progenitor cells into mature, K14-labeled basal and 
squamous cells. 
In Chapter 3, we proposed that neonatal xenoestrogen exposure initiates the 
development of chimeric endometrial epithelial cells with K14 and K18 labeling that serve as a 
population of cancer progenitor cells. Here, we again observed the DES-induced K14 and K18-
labeled chimeric epithelial cells in carcinomas in both DES-exposed Six1+/+ and Six1d/d mice. 
This cell phenotype became more prominent in the DES-exposed Six1d/d mice, particularly in the 
uterine horns as indicated by the higher incidence of atypical hyperplastic lesions comprised of 
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chimeric epithelial cells and lacking basal cells (67% of DES-exposed Six1d/d mice had atypical 
hyperplasia lacking basal cells, compared with 0% of DES-exposed Six1+/+ mice). However, it is 
not clear at this point whether the prominence of the chimeric epithelial cell type within DES-
exposed Six1d/d mice was due to an actual increase in the number of these cells (resulting from 
a lack of SIX1-mediated differentiation) or simply due to the fact that they were easier to identify 
in the absence of more conspicuous basal cells. However, it could also be attributed to an 
increase in the chimeric epithelial cell population. Interestingly, there was also a slight increase 
in the overall incidence of carcinomas (78% incidence in DES-exposed Six1d/d mice compared 
with 40% in DES-exposed Six1+/+ mice), although there are insufficient numbers to determine a 
significant difference at this age point. It is possible, that ablation of SIX1 leads to an increase in 
susceptibility to DES-induced endometrial carcinoma by decreasing epithelial differentiation into 
mature luminal (K18+) or basal cells (K14+) and instead increasing the pool of chimeric 
epithelial cells (K14+/K18+) that serve as cancer progenitor cells which are more susceptible to 
transformation. 
Our findings support the role of SIX1 as a differentiating factor in the endometrium, 
specifically in the uterine horns. This idea is supported by previous studies which demonstrated 
that SIX1 regulates stem cell populations in muscle, kidney, and mammary gland in a tissue-
specific manner (Le Grand et al., 2012; Swetha et al., 2011; McCoy et al., 2009). For example, 
ablation of Six1 during muscle regeneration results in an increased number of muscle stem cells 
and diminished capacity of muscle stem cells to regenerate functional muscle (Le Grand et al., 
2012). In contrast, overexpression of SIX1 in mammary tissue results in an increased population 
of progenitor-like cells and induces mammary gland tumors of various histologic subtypes 
(McCoy et al., 2009). Together, these data indicate the dynamic role of SIX1 in regulating 
progenitor cell populations and promoting differentiation. Furthermore, these data suggest that 
aberrant uterine SIX1 may play a role in regulating differentiation of the chimeric epithelial cells 
to more mature basal cells following neonatal xenoestrogen exposure. If ablation of SIX1 indeed 
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leads to an increased population of chimeric epithelial cells that serve as cancer progenitor 
cells, it is possible that this may actually increase susceptibility to estrogen-promoted 
carcinogenesis. Future studies with increased animal numbers, additional later time points, and 
quantitative analysis of this undifferentiated cell population are needed to help evaluate these 
ideas.  
The inhibitory effects of Six1 ablation on DES-induced basal cell and squamous 
metaplasia aligns with the previously described role of SIX1 in promoting progenitor cell 
differentiation (Le Grand et al., 2012; Swetha et al., 2011; McCoy et al., 2009). Therefore, we 
propose a model for the role of aberrant uterine SIX1 in promoting basal-type differentiation in 
DES-induced chimeric epithelial cells seeded in the uterus following neonatal DES exposure 
(Fig. 4-5). During neonatal development, xenoestrogen exposure establishes a bipotential 
population of SIX1-labeled chimeric epithelial cells (SIX1+/K14+/K18+). Some of these less 
differentiated cells will differentiate into mature basal cells (K14+/K18-) with SIX1 acting as a 
major differentiation factor, at least in the uterine horns. These basal cells encircle normal 
luminal columnar glandular epithelial cells (K14-/K18+) and may in some cases progress to 
squamous metaplasia. SIX1-positive cell types that exhibit more mature luminal (K14-/K18+) or 
basal (K14+/K18-) differentiation may be inherently more resistant to transformation. However, 
in the absence of Six1, a subset of K14 and K18-labeled chimeric epithelial cells will fail to 
differentiate and be actively maintained as a progenitor cell population that is susceptible to 
carcinogenesis with chronic endogenous estrogen exposure. Thus, we propose that SIX1-
mediated differentiation provides a protective mechanism by decreasing the number of less 
differentiated K14 and K18-labeled chimeric epithelial cells. Further studies investigating 
differentially expressed genes in DES-exposed Six1+/+ and Six1d/d mice may reveal SIX1-
regulated pathways involved in DES-induced metaplasia. In sum, SIX1 is a biomarker of DES-
induced changes in the uterus and regulates differentiation patterns resulting from early life 
estrogen exposure. While SIX1 is not required for endometrial carcinogenesis, our findings 
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suggest that it may actually decrease DES-induced carcinogenesis by driving differentiation 
and/or expansion of more mature luminal and basal cell types. 
Here we also showed that transgenic SIX1 expression alone does not induce uterine 
carcinogenesis or the appearance of any other pathologies characteristic to neonatal DES-
exposure, including basal cell metaplasia or the appearance of these undifferentiated cells, by 6 
months of age. However, it is possible that these animals were too young to observe uterine 
changes or that potential SIX1-mediated changes require an abnormal uterine environment 
established by neonatal xenoestrogen exposure (eg. altered cyclicity, upregulated inflammatory 
pathways, obesity). In a mouse model in which SIX1 was conditionally overexpressed in the 
mammary glands, tumors were not observed until 18 months of age, and even at that age the 
cancer incidence was low (~24%) (McCoy et al., 2009). Additional later time points may reveal a 
phenotype in our model of uterine SIX1 overexpression.  
Another potential explanation for a lack of uterine phenotype in our SIX1 overexpression 
model is the low level of transgenic SIX1 expression in adult mice compared with adult mice that 
were neonatally DES-exposed mice. Previous studies have shown not only does neonatal DES-
exposure induce aberrant SIX1, but it also causes Six1 transcript expression to become 
estrogen responsive with Six1 transcript and protein levels increasing with age (Jefferson et al., 
2011; Jefferson et al., 2013; Suen et al., 2016). Furthermore, adult xenoestrogen exposure 
cannot induce uterine SIX1 in the absence of neonatal exposure. Therefore, it is possible that 
carcinogenesis does not occur because SIX1 is not programmed to become estrogen 
responsive and therefore does not continue to increase with age in the SIX1 overexpression 
model. Future studies using SIX1 overexpressing mice that are neonatally exposed to 
xenoestrogens may reveal that SIX1 overexpression has a promotional effect with earlier or 
more invasive cancer development.  
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 Table 4-1 Incidence of reproductive tract abnormalities in control or neonatally DES-
exposed Six1 wildtype or conditional knockout mice at 6 months of age 
    CON   DES 
Site Pathology  Six1+/+ Six1d/d   Six1+/+ Six1d/d 
Vagina Adenosis  0/10 (0%) 0/10 (0%)   3/10 (30%) 2/9 (22%) 
Cervix Edema  2/10 (20%) 2/10 (20%)  9/10* (90%) 6/9 (67%) 
Uterus Cystic change  0/10 (0%) 1/10 (10%)  2/10 (20%) 2/9 (22%) 
 Adenomyosis  0/10 (0%) 0/10 (0%)   5/10* (50%) 9/9* (100%) 
 Basal cell metaplasia  1/10 (10%) 0/10 (0%)  10/10* (100%) 9/9* (100%) 
 Squamous metaplasia1  0/10 (0%) 0/10 (0%)   7/10* (70%) 2/9 (22%) 
 Atypical hyperplasia 
without basal cells2  0/10 (0%) 0/10 (0%)  0/10 (0%) 6/9* (67%) 
 Atypical hyperplasia 
with basal cells3  0/10 (0%) 0/10 (0%)   8/10* (80%) 9/9* (100%) 
 Carcinoma  0/10 (0%) 0/10 (0%)  4/10 (40%) 7/9* (78%) 
Abbreviations: CON, control; DES, diethylstilbestrol 
*Significant using one-tailed Fisher exact test P<0.05 compared to corresponding CON mice 
n=9-10 mice per treatment and genotype group as indicated in the table 
1Stratified squamous cells replacing glandular epithelium; distinct from a single layer of basal cells 
2Gland-only atypical hyperplasia lacking basal cell differentiation predominantly in uterine horns 
3Atypical hyperplasia with associated basal cell metaplasia 
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 Table 4-2 Expression of immunohistochemical markers in control or neonatally DES-
exposed Six1 wildtype or conditional knockout mice at 6 months of age 
    CON   DES 
IHC Site  Six1+/+ Six1d/d   Six1+/+ Six1d/d 
SIX1         
 Vaginal epithelium  10/10 (100%) 0/10* (0%)  10/10 (100%) 1/9*ǂ (11%) 
 Labeling index1  1.6 0.0   1.8 0.1 
 Nonneoplastic 
endometrial epithelium  1/10ǂ (10%) 0/10 (0%)   10/10* (100%) 0/9 (0%) 
 Labeling index1  0.1 0.0  2.2 0.0 
 Neoplastic  
endometrial epithelium2  NA NA  4/4 (100%) 0/7 (0%) 
 Labeling index1  NA NA   2.8 0.0 
K14        
 Vaginal epithelium  10/10 (100%) 10/10 (100%)  10/10 (100%) 9/9 (100%) 
 Labeling index1  3.0 3.0   3.0 3.0 
 Nonneoplastic 
endometrial epithelium  2/10 (20%) 0/10 (0%)   10/10* (100%) 9/9* (100%) 
 Labeling index1  0.2 0.0  2.2 1.0 
 Neoplastic  
endometrial epithelium3  NA NA  4/4 (100%) 7/7 (100%) 
 Labeling index1  NA NA   2.3 2.1 
Abbreviations: CON, control; DES, diethylstilbestrol; NA, not applicable 
*Significant using one-tailed Fisher exact test P<0.05 compared to corresponding wildtype 
mice 
n=9-10 mice per exposure and genotype group as indicated in the table 
ǂEquivocal SIX1 labeling 
1Average qualitative severity score from 0 to 4 for labeling across the group 
2Number of mice with SIX1 labeled neoplastic lesions out of animals with carcinoma 
3Number of mice with K14 labeled neoplastic lesions out of animals with carcinoma 
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Figure 4-1 Conditional Six1 ablation prevents uterine Six1 transcript and protein 
expression in mice neonatally exposed to DES. Figure legend continues on the following 
page.  
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Figure 4-1 Conditional Six1 ablation prevents uterine Six1 transcript and protein 
expression in mice neonatally exposed to DES. A. Schematic representation of Cre-LoxP 
mediated Six1 gene inactivation. B. Six1 transcript expression on PND5 (n=4 mice per 
exposure group and genotype; mean ± S.E.M. is plotted. Two-way ANOVA with Tukey test for 
multiple comparison: *, P<0.05) or at 6 months of age (n=5-9 mice per exposure group and 
genotype; mean ± S.E.M. is plotted. Two-way ANOVA with Tukey test for multiple comparison: 
*, P<0.05). C. Immunoblot of SIX1 in whole uterine tissue from two individual mice per treatment 
group and genotype on PND5 or at 6 months of age; 10 ug of protein from one mouse per lane. 
D. SIX1 labeling in vaginal epithelium from control Six1+/+ and Six1d/d mice at 6 months of age. 
Representative images were taken at 20x. 
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Figure 4-2 SIX1 is not required for DES-induced endometrial carcinogenesis. Figure 
legend continues on the following page.  
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Figure 4-2 SIX1 is not required for DES-induced endometrial carcinogenesis. A. Incidence 
of endometrial carcinoma in control and DES-exposed Six1+/+ and Six1d/d mice at 6 months of 
age. n=9-10 mice per exposure group and genotype. One-tailed Fisher exact Test: *, P<0.05 
compared to corresponding control mice. B. Endometrial carcinoma in the uterine body of DES-
exposed Six1+/+ (top) and Six1d/d (bottom) mice at 6 months of age. C. Basal cell metaplasia 
within a gland in the uterine horn of a DES-exposed Six1+/+ mouse (top; arrows indicate 
characteristic K14 and K18 labeling pattern of basal and luminal cells) and atypical chimeric 
epithelial cells in a luminal cell-only hyperplastic lesion in the uterine horn of a neonatally DES-
exposed Six1d/d mouse (bottom; arrowheads indicate mixed K14 and K18 labeling in luminal 
cells with no apparent basal cells). Representative images were taken at 20x (B) and 40x (C). 
  
87 
 
 
Figure 4-3 Conditional Six1 ablation abolishes DES-induced basal cell metaplasia within 
the uterine horns. Figure legend continues on the following page. 
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Figure 4-3 Conditional Six1 ablation abolishes DES-induced basal cell metaplasia within 
the uterine horns. A. Representative image of K14 labeling (left) and positive pixel detection 
(red=strong positive pixels; right) were taken at 20x. B. Image analysis regions of interest for 
uterine horn (dark blue outline) or uterine body (light blue outline). C. Number of K14-positive 
pixels in a single uterine horn from DES-exposed Six1+/+ and Six1d/d mice and genotype controls 
as an indication of basal-squamous metaplasia. n=9-10 mice per exposure group and genotype; 
mean ± S.E.M. is plotted. Two-way ANOVA with Tukey test for multiple comparison: *, P<0.05. 
D. Number of K18-positive pixels in a single uterine horn from DES exposed Six1+/+ and Six1d/d 
mice and genotype controls as an indication of glandular and luminal epithelium. n=9-10 mice 
per exposure group and genotype; mean ± S.E.M. is plotted. Two-way ANOVA with Tukey test 
for multiple comparison: *, P<0.05; NS=not significant. E. Number of K14-positive pixels in the 
uterine body of DES exposed Six1+/+ and Six1d/d mice and genotype controls as an indication of 
basal/squamous metaplasia. n=9-10 mice per exposure group and genotype; mean ± S.E.M. is 
plotted. Two-way ANOVA with Tukey test for multiple comparison. 
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Figure 4-4 Overexpression of SIX1 in the uterus does not induce endometrial carcinoma 
by 6 months of age. Figure legend continues on the following page. 
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Figure 4-4 Overexpression of SIX1 in the uterus does not induce endometrial carcinoma 
by 6 months of age. A. Schematic representation of Cre-LoxP mediated SIX1 overexpression. 
B. Immunoblot of SIX1 and Flag in whole uterine tissue from two individual mice per treatment 
group and genotype on PND5 or at 6 months of age; 10 ug of protein from one mouse per lane; 
WT CON and DES-exposed mouse added for comparison of WT SIX1 and Tg SIX1. C. Uterine 
SIX1 labeling in a Six1Tg/+ mouse (left) and Six1Tg/d;Pgr-cre mouse (right). Arrow indicates SIX1 
positive epithelial cells, arrowhead indicates SIX1 positive stromal cells, asterisk indicates SIX1 
positive myometrium. Representative images were taken at 20x. 
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Figure 4-5 Model of SIX1 as an epithelial differentiating factor. 
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CHAPTER 5 – CONCLUSIONS, PERSPECTIVES, AND FUTURE DIRECTIONS 
 
Understanding the mechanisms of endometrial carcinogenesis following neonatal 
xenoestrogen exposure continues to be of interest to regulatory agencies, industry, and the 
population at large due to the widespread presence of naturally-occurring and manufactured 
xenoestrogens found in the environment, food, and consumer products. Identification of 
molecular signatures and a mode of action could be used to develop new or aid existing toxicity 
screening to protect human health. However, despite this model having been extensively 
studied for over 25 years, a clear mechanism remains to be determined. Newbold et al. (2007) 
first proposed that altered uterine gene expression functioned to promote endometrial 
carcinogenesis in this model long after the timing of exposure. Subsequent studies primarily 
performed by the Newbold and Williams laboratories aimed to understand specific pathways 
altered by neonatal xenoestrogen that contribute to adverse reproductive effects later in life 
(Newbold et al., 2007; Jefferson et al., 2011; Jefferson et al., 2013). Permanent aberrant 
expression of the oncofetal protein SIX1 following neonatal xenoestrogen exposure appeared to 
be a likely candidate for mediating carcinogenesis in this model and formed the basis for the 
research presented in this dissertation. 
In the research presented here, I investigated both the correlation and causation of SIX1 
in development of endometrial carcinoma following neonatal xenoestrogen exposure. I showed 
that SIX1 is a biomarker for neonatal xenoestrogen exposure and disease development, can be 
used to identify aberrant cell populations in exposed uteri, and is also present in human 
endometrial cancer. However, I also showed that SIX1 is neither necessary for DES-induced 
endometrial cancer, nor sufficient to induce cancer by 6 months of age in the absence of 
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neonatal xenoestrogen exposure. Instead, I found that SIX1 expression induced by neonatal 
xenoestrogen exposure appears to act as a cellular differentiation factor and may regulate a 
population of endometrial progenitor cells that are susceptible to transformation. 
 Although other specific genes and gene networks, such as lactoferrin, P63, and TGFβ 
(Newbold et al., 2007; Couse et al., 2001), have been proposed as potential mechanisms for 
endometrial carcinogenesis in this exposure model, I now think it is unlikely that a single gene is 
responsible for carcinogenesis and that instead, this model relies on several mechanisms that 
act synergistically to produce adverse effects. In this exposure model, cancer appears to arise 
due to a complex combination of the timing of exposure during cell patterning and 
differentiation, a plethora of transient and permanent ER-mediated downstream effects that 
occur during initiation by neonatal exposure and subsequent promotion by later endogenous 
estrogens, and epigenetic modifications (Jefferson et al., 2011; Jefferson et al., 2013). 
Together, these factors (and likely others that remain unknown) highlight that xenoestrogen 
exposure and disease development in this model does not fit simply into the current way most 
toxicants are defined, with a straightforward mode of action and toxic/nontoxic criterion. 
Therefore, rather than continue with narrow studies targeting a single gene or pathway, and 
trying to identify a single mode of action pathway, I think the field should expand its focus to 
understand xenoestrogen-induced molecular changes on a global level. I also recommend that 
particular attention should be paid to global epigenetic modifications that result from exposure, 
as they likely play a prominent role in disease development, and might be the best way to 
identify a collection of molecular signatures of exposure and disease that could be used to 1) 
extrapolate animal data to humans, 2) connect exposure induced epigenetic modifications with 
adverse effects, and 3) be extended to establish toxicity screens during sensitive windows in 
development. 
 
94 
Investigating Epigenetic Modifications to Identify Molecular Signatures for Toxicity 
Studies 
Previously, chromatin immunoprecipitation quantitative polymerase chain reaction 
(ChIP-PCR) experiments demonstrated that neonatal DES exposure results in permanent 
alterations in Six1 gene locus-specific epigenetic marks, including a significantly increased 
association with several activating histone marks (H3K4me3, H3K9ac, and H4K5ac) (Jefferson 
et al., 2013). The data presented here supported a link between exposure, locus-specific 
epigenetic modifications, and disease development, by showing that SIX1 is involved in 
aberrant DES-induced endometrial epithelial cell differentiation. However, these data show only 
a fraction of the story. Future epigenetic regulation studies, such as histone ChIP-seq, to 
explore in-depth alterations in epigenetic marks paired with gene expression studies (RNA-seq) 
in the neonatal xenoestrogen exposure model will provide a much fuller understanding of the 
molecular mechanisms of hormonal carcinogenesis. Recent advances in experimental 
techniques including cheaper and faster sequencing and ChIP protocols using smaller tissue 
samples now make global investigation of altered pathways feasible.  
In addition to investigating the unchallenged neonatal xenoestrogen exposure model 
(lacking subsequent exogenous estrogen exposure), manipulation of the promotion phase (2nd-
hit) may help tease out cancer mechanisms. Several studies looking at altered gene expression 
in this model show that it is difficult to separate changes that are associated with carcinogenesis 
and other unrelated gene expression changes (eg. those that may contribute to other 
phenotypes or have no effect at all) (Newbold et al., 2007; Huang et al., 2005; Jefferson et al., 
2011). These studies predominantly focus on gene expression changes in control versus 
exposed animals at early time points (PND5, puberty). Several studies have also indicated that 
estradiol working through ERα mediates carcinogenesis in this model (Newbold et al., 1990; 
Leavitt et al., 1981; Couse et al., 2001; Lubahn et al., 1993). Future gene expression studies 
may elucidate the combination of changes that cause xenoestrogen induced carcinogenesis. 
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These include 1) comparing control and exposed mice at PND5 and the cancer endpoint (18 
months of age) to reveal permanently altered pathways that could connect exposure with 
disease development; 2) comparing neontally xenoestrogen-exposed intact and ovariectomized 
mice +/- estradiol challenge, and 3) comparing neonatally-xenoestrogen exposed wildtype and 
conditional ERα knockout mice may reveal estrogen regulated pathways that are necessary for 
cancer promotion. 
Using the DES-exposed Six1 Conditional Knockout Mouse as a Model for Normal and 
Abnormal Endometrial Epithelial Differentiation 
Previous studies show that anterior-posterior patterning and cellular differentiation of the 
female reproductive tract is driven by homeobox transcription factors that coincide with specific 
female reproductive tract regions (Ma, 2009; Kobayashi and Behringer, 2003; Jefferson et al., 
2012). Neonatal xenoestrogen exposure posteriorizes expression of these regulatory networks 
so factors normally controlling squamous epithelial differentiation in the vagina (eg. HOXA13, 
P63, SIX1) become expressed in the uterus where they facilitate basal cell differentiation 
(phenotype described in Chapter 3, evidence for role of SIX1 in Chapter 4). Several studies, 
including data presented in Chapter 3, show that the basal cell marker P63 is essential for 
vaginal epithelial differentiation and can be used as a marker of uterine basal cell differentiation 
(Kurita et al., 2004; Kurita, 2011). P63 and SIX1 have similar expression patterns in both normal 
vaginal epithelium and abnormal xenoestrogen-induced uterine epithelial differentiation 
(Chapter 3). The vaginal and cervical epithelium in control P63 null mice differentiates into 
uterine epithelium (Kurita et al., 2004). However, neonatally DES-exposed P63 null mice still 
develop basal cell and squamous metaplasia within the uterine body and horns (Kurita et al., 
2004). In contrast, the vaginal and cervical epithelium in control Six1 conditional knockout mice 
remains morphologically normal, but neonatally DES-exposed Six1 conditional knockout mice 
lack characteristic basal cell and squamous metaplasia within the uterine horns (Chapter 4). 
Interestingly, DES-induced uterine SIX1 transcript and protein expression precedes P63 
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(unpublished data). These data highlight the complexity of region-specific differentiation 
patterns, but also suggest that there is a common upstream regulator of P63 and SIX1 that 
controls location and exposure specific expression patterns and subsequent cell differentiation. 
Future studies using the DES-exposed Six1 conditional knockout model may contribute to 
understanding the molecular mechanisms of normal and abnormal female reproductive tract 
epithelial differentiation. To understand how DES-induced SIX1 alters endometrial epithelial 
differentiation, I propose that future gene expression studies should be performed comparing 
uteri from control and DES-exposed SIX1+/+ and Six1d/d mice. These comparisons may reveal 
altered regulatory networks that control uterine-specific basal cell differentiation. These uterine 
regulatory networks can be further compared to those present in normal and P63 null (uterine-
like) vagina. Together, these data may reveal region-specific control of vaginal and uterine-like 
epithelium within the vagina and uterine and vaginal-like epithelium within the uterus. 
Investigating SIX1 as an Exposure and Disease Biomarker in Women Prenatally Exposed 
to DES 
As described previously, the reproductive cancer most directly correlated with prenatal 
DES exposure is vaginal clear-cell adenocarcinoma among women exposed during early 
gestation (Troisi et al., 2007). Thus far, no increased risk of endometrial carcinoma has been 
reported in association with prenatal DES exposure (IARC, 2012).  However, postmenopausal 
follow up studies have not yet been completed as prenatally DES-exposed women currently 
range in age from ~44-78. In the mouse model of hormonal carcinogenesis, endometrial 
carcinoma development was most prominent in late life (12-18 months of age) suggesting that a 
similarly altered risk of endometrial cancer development in DES-exposed women might not 
become apparent until postmenopausal studies have been completed. In the data presented 
here, I show that although SIX1 does not play a direct role in carcinogenesis, it may mediate a 
putative cancer progenitor cell population, and is also an excellent biomarker for neonatal 
xenoestrogen exposure, abnormal differentiation, and neoplasia. I also showed that SIX1 is 
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present in neoplastic cells within human endometrial cancer lesions but not in normal cancer-
adjacent tissue, or normal endometrial tissue from patients without cancer. It is unknown if the 
endometrial cancer biopsies analyzed in Chapter 2 came from women who were prenatally 
exposed to DES. However, these data support further investigation for the use of SIX1 as an 
exposure and disease biomarker. It would be particularly informative to investigate uterine SIX1 
expression in cohorts of women with known prenatal DES exposure such as the NIEHS Sister 
Study or the Nurse’s Study (D'Aloisio et al., 2010; Mahalingaiah et al., 2014). 
Investigating the Windows of Susceptibility 
There are many published studies demonstrating that different windows of exposure to 
estrogenic chemicals have distinct outcomes in terms of reproductive tract development. Most 
of the studies described here, including the original research presented in Chapters 2-4, 
investigate adverse effects resulting from early life xenoestrogen exposure (prenatal exposure 
or exposure up to postnatal day 5). However, the window of susceptibility in the neonatal 
xenoestrogen exposure model, and when it closes, is not well understood. For instance, gland 
development defines another period in female reproductive tract differentiation that could be 
particularly susceptible to disruption by xenoestrogens. Gland development occurs after the 
classic PND1-5 xenoestrogen exposure, beginning around PND7, and is not complete until 
PND15 (Cooke et al., 2013). Most studies compare prenatal exposures to early neonatal 
exposures, (Newbold and McLachlan, 1982; Leavitt et al., 1981), but comparisons of effects 
resulting from xenoestrogen exposure during different postnatal windows has not been 
completed. One study in Eker rats showed that DES exposure during PND3-5 and PND10-12, 
but not following exposure during PND17-19, resulted in increased incidences of leiomyoma, 
indicating that the window of susceptibility closed by this time (Cook et al., 2007). The window of 
susceptibility for DES-induced endometrial carcinoma in this mouse model may continue up 
until the completion of gland development on PND15. Future studies could investigate the 
various exposure windows. Investigating other exposure windows in this animal model could be 
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useful for understanding if SIX1 is a neonatal-specific exposure biomarker or if it could be 
extended to exposures during other time points.  
Future studies investigating endometrial cancer and uterine SIX1 expression in cohorts 
of women exposed to DES during other sensitive developmental periods may be useful for 
understanding sensitive windows in humans. Cohorts could include women exposed to DES 
during pregnancy, women prescribed DES as a hormone replacement therapy during 
menopause (IARC, 1987; IARC, 2012), and adolescent girls exposed to DES to decrease their 
adult height (Venn et al., 2004). 
Taken together, these studies will help us understand the molecular mechanisms of 
adverse effects caused by xenoestrogen exposures. 
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